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Abstract 
Cardiovascular disease is a leading cause of morbidity and mortality in developed 
countries. It is mainly caused by atherosclerosis, a chronic inflammatory disease that it is 
characterized by the formation of plaques in the arterial intima between the endothelium 
and the underlying smooth muscle cells of the media.  
Macrophages are the first inflammatory cells to invade atherosclerotic lesions and a main 
component of atherosclerotic plaques. The emerging understanding of macrophage 
phenotypes and their functions in the atherosclerotic plaque has led to the consensus that 
pro-inflammatory M1 macrophages are pro-atherogenic while M2 macrophages may promote 
plaque stability, primarily though their tissue repair and anti-inflammatory properties. As 
such, modulating macrophage function to promote plaque stability is an exciting therapeutic 
prospect.  
MicroRNAs are a class of small noncoding RNAs that have gained status as important post-
transcriptional regulators of gene expression and are likely involved in key cellular functions, 
including macrophage polarization. Thus, certain miRNAs will be able to modulate the 
magnitude of an inflammatory response, by changing expression levels of cytokines, surface 
receptors and other inflammation-related molecules, which will have consequences for 
macrophage phenotype.  
In this context, the goal of this study was to use miRNAs to reduce M1-like macrophages, 
promoting inflammation resolution. Also we aimed to evaluate the molecular mechanism 
underlying such effect and the functional consequences for smooth muscle cell recruitment.  
In order to achieve our goal, we polarized primary monocyte-derived macrophages into M1 
and M2c phenotypes, by stimulating them with LPS and IL-10 respectively. CD86 and CD206 
were used as markers to confirm M1 and M2c polarizations by flow cytometry.  Next, we 
evaluated the expression of microRNA-195 by reverse transcription - real-time quantitative 
polymerase chain reaction, using Taqman assays. In silico predictions for microRNA-195 
targets involved in Toll like receptors inflammatory pathways were performed using distinct 
databases. To analyze the biological effect of microRNA-195 in macrophage phenotype and its 
effect on the expression of these predicted targets, we performed in vitro transfections of 
microRNA-195 mimics followed by an M1 stimulus with LPS+IFN-γ in THP-1 macrophages. At a 
functional level, the impact of microRNA-195 expression in THP-1 macrophages was also 
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evaluated. Migration assays were performed using inserts with PET membranes of 8 µm pore 
size in which human umbilical artery smooth muscle cells were allowed to migrate for 24 
hours over differently stimulated THP-1 macrophages. 
The results obtained showed that microRNA-195 was upregulated in macrophages treated 
with IL-10 compared with LPS treated macrophages and control (untreated) group.  In silico, 
TLR2 and several Mitogen Activated Protein Kinases (MAPK) were predicted to be targets of 
this miRNA. Importantly, further experiments confirmed that TLR2 expression in LPS+IFN-γ 
stimulated THP-1 macrophages was significantly reduced by the transfection of microRNA-195 
mimics compared with scrambled-transfected and non-transfected cells. Moreover, 
phosphorylated forms of proteins p54 (JNK1), p46 (JNK2/SAPK) and p38 - MAPK that are part 
of the downstream TLR signaling pathway - were all downregulated by microRNA-195. 
Functionally, migration assays results revealed that microRNA-195-THP-1 macrophages have 
significantly less capability to recruit human umbilical artery smooth muscle cells compared 
with scrambled-transfected or non-transfected pro-inflammatory THP-1 macrophages. 
In conclusion, we show that microRNA-195 is involved in macrophage polarization and 
inhibits the Toll-like receptor inflammatory pathway by reducing the levels of TLR2 and the 
phosphorylated forms of downstream proteins p54, p46 and p38 in pro-inflammatory 
conditions. Moreover, at a functional level, microRNA-195 inhibits the macrophage-mediated 
recruitment of smooth muscle cells.  
Thus, we identified microRNA-195 as a new potential anti-inflammatory and anti-
atherogenic agent to promote inflammation resolution in cardiovascular research. These 
results are being prepared as a manuscript, to be submitted for publication. 
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Resumo 
As doenças cardiovasculares são a maior causa de morbidade e mortalidade nos países 
desenvolvidos. Estas são principalmente causadas pela aterosclerose, uma doença 
inflamatória crónica que é caracterizada pela formação de placas na túnica íntima arterial 
entre o endotélio e as células do músculo liso subjacentes. 
Os macrófagos são as primeiras células inflamatórias a invadir as lesões ateroscleróticas e 
são o maior componente das placas. O conhecimento cada vez mais aprofundado acerca dos 
diferentes fenótipos dos macrófagos e das suas funções na placa aterosclerótica tem levado 
ao consenso de que os macrófagos pró-inflamatórios do tipo M1 são pró-aterogénicos, 
enquanto que os macrófagos do tipo M2 promovem a reparação de tecidos e têm propriedades 
anti-inflamatórias. 
Os microRNAs são uma classe de pequenos RNAs não codificantes que têm ganho 
relevância como importantes reguladores da expressão dos genes após a sua transcrição e 
estão envolvidos em funções celulares chave, incluindo na polarização dos macrófagos. Os 
microRNAs são capazes de modular a magnitude de uma resposta inflamatória afetando os 
níveis de expressão de citoquinas, de recetores de superfície e de outras moléculas 
inflamatórias e, deste modo, modificar também o fenótipo dos macrófagos.  
O objetivo deste estudo foi utilizar microRNAs para reduzir a polarização de macrófagos 
para o fenótipo M1, promovendo assim a resolução da inflamação. Em particular, procurámos 
desvendar os mecanismos moleculares por detrás do efeito observado e também as 
consequências funcionais, ao nível do recrutamento das células do músculo liso da artéria 
umbilical.  
Para atingir esses objetivos, polarizámos macrófagos derivados de monócitos primários 
para fenótipos do tipo M1 e M2c, com LPS e IL-10, respetivamente. Os marcadores de 
superfície CD86 e o CD206 foram utilizados para confirmar a polarização, por citómetria de 
fluxo. De forma a investigar microRNAs expressos de forma diferenciada nos dois estados de 
polarização, avaliámos a expressão do microRNA-195 por RT-PCR quantitativo. Utilizando 
várias bases de dados, realizámos previsões in silico de possíveis alvos do microRNA-195 
envolvidos nas vias inflamatórias dos recetores Toll-like. Para analisarmos o efeito biológico 
do microRNA-195 nos macrófagos e o seu efeito na expressão destes alvos previstos, 
realizámos transfecções in vitro, em macrófagos THP-1, do microRNA-195 seguidas de um 
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estímulo pró-inflamatório com LPS+IFN-γ. A nível funcional, o impacto da expressão do 
microRNA-195 em macrófagos THP-1 foi também avaliado. Neste sentido, foram realizados 
ensaios de migração usando inserts com membranas PET porosas (8 µm) nos quais foram 
colocadas células humanas do músculo liso da artéria umbilical que migraram durante 24 
horas atraídos por macrófagos THP-1 estimulados de diferentes formas.  
Os resultados revelaram que o microRNA-195 é sobre-expresso em macrófagos estimulados 
com IL-10 por comparação com macrófagos estimulados com LPS e com o grupo de controlo 
(não estimulados). As previsões in silico indicaram o TLR2 como possível alvo deste microRNA. 
A expressão do TLR2 em macrófagos THP-1 estimulados com LPS+IFN-γ foi significativamente 
reduzida pela transfecção do microRNA-195 por comparação com as células transfectadas com 
o controlo negativo ou com as células não transfectadas. Além disso, os níveis das proteínas 
fosforiladas p54 (JNK1), p46 (JNK2/SAPK) e p38, que fazem parte da via de sinalização dos 
recetores Toll-like, foram diminuídos pelo microRNA-195. Os resultados dos ensaios de 
migração revelaram que os macrófagos THP-1 transfectados com o microRNA-195 têm menos 
capacidade para recrutar células humanas do músculo liso da artéria umbilical do que os 
macrófagos THP-1 transfectados com o controlo negativo ou não transfectados. 
Em conclusão, mostramos que o microRNA-195 está envolvido na polarização dos 
macrófagos e na inibição, em condições pró-inflamatórias, da via de sinalização dos recetores 
Toll-like, reduzindo os níveis do TLR2 e das formas fosforiladas das proteínas subjacentes 
p54, p46 e p38. Para além disso, observamos igualmente um papel anti-aterogénico, uma vez 
que o microRNA-195 inibe o recrutamento de células do músculo liso por parte dos 
macrófagos. 
Assim, identificamos o microRNA-195 como um novo potencial agente anti-inflamatório e 
anti-aterogénico para a resolução da inflamação na investigação cardiovascular. Está a ser 
preparado um manuscrito com os resultados aqui apresentados, para ser submetido para 
publicação. 
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Chapter 1 
Introduction 
1.1 Inflammation in cardiovascular disease 
 
Cardiovascular disease (CVD) remains the leading cause of death among Europeans and 
around the world [1]. Cerebrovascular accident, acute myocardial infarction and coronary 
heart disease are the most common forms of CVD. A recent study by Nichols et al. reporting 
the burden of CVD across European countries concluded that, despite recent decrease in 
mortality rates, CVD is still responsible for over 4 million deaths per year, close to half of all 
deaths in Europe [1]. Globally, CVD caused 51% of deaths among women and 42% among men 
[1]. In Portugal, data released by “Direcção Geral de Saúde” shows that nearly 30% of deaths 
in 2012 were related to circulatory system diseases, which also configures the first cause of 
death in the country [2].  
Atherosclerosis is frequently the underlying pathological feature of CVD. Atherosclerosis is 
a slowly progressive chronic disease, which may start developing during childhood, and it is 
characterized by the formation of plaques in the arterial intima, between the endothelium 
and the underlying smooth muscle cells of the media [3]. These plaques are formed by foam 
cells, immune cells, vascular endothelial cells (ECs), migrated smooth muscle cells (SMCs), 
platelets, extracellular matrix, and accumulated modified lipids [4]. Morphologically, 
advanced plaques are composed of a necrotic core and overlying fibrous cap and those with a 
relatively large core and thin cap are considered unstable and are vulnerable to rupture [5]. 
Upon cap rupture, the blood is exposed to thrombogenic material, which leads to vessel 
occlusion. 
Hypertension, diabetes, high levels of cholesterol associated with tobacco use and obesity 
are considered the major atherosclerotic and CVD risk factors [1]. For that reason the 
treatment of these diseases may firstly include lifestyle changes and then all the medical and 
surgical procedures and cardiac rehabilitation. Currently, treatment of atherosclerosis 
focuses on the relieving symptoms, reducing risk factors in an effort to slow or stop the 
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buildup of plaque, lowering the risk of blood clots forming, widening or bypassing plaque-
clogged arteries and preventing atherosclerosis-related diseases [6]. To slow the progress of 
plaque buildup, doctors usually prescribe drugs to lower cholesterol levels, blood pressure or 
to prevent blood clots from forming. Statins are considered the best drugs for lowering LDL 
cholesterol while blood thinners, as anti-platelets, are used to prevent clots formation, 
reducing the risk of heart attacks or strokes [6]. In the cases of severe atherosclerosis other 
medical procedures or surgeries may be necessary. Angioplasty is a procedure that is used to 
open blocked or narrowed arteries [7]. Angioplasty can improve blood flow to the heart and 
relieve chest pain. Coronary artery bypass grafting (CABG) is another type of surgery, in which 
arteries or veins from other areas of the body are used to bypass narrowed coronary arteries. 
The healthy blood vessel redirects blood around the blocked artery, improving blood flow [8]. 
Finally, carotid endarterectomy is a surgery to remove plaque buildup from the carotid 
arteries in the neck, in a procedure which restores blood flow to the brain, helping to prevent 
a stroke [6]. 
These are the most common and efficient treatments used to overcome late 
atherosclerotic lesion problems; however, researchers continue to study the pathology of the 
lesion in order to better understand which mediators could be used to control the 
inflammation during the development of the disease. Inflammation plays a role in all stages 
of atherosclerosis [9]. This disease involves chronic inflammation at every stage, from 
initiation to progression, and eventually plaque rupture. In atherosclerosis, the normal 
homeostatic functions of the endothelium are altered, promoting an inflammatory response 
[10]. Initially, adhesion molecules expressed by inflamed endothelium recruit leukocytes, 
including monocytes, which then penetrate into the intima, predisposing the vessel wall to 
lipid accretion or vasculitis [3]. Inflammatory mediators enhance uptake of modified 
lipoprotein particles and formation of lipid-laden macrophages [11]. T cells also enter the 
intima and, simultaneously with macrophages, secrete cytokines, which subsequently amplify 
the inflammatory response and promote the migration and proliferation of intimal smooth 
muscle cells, promoting fibrous cap formation [12]. Later in the process, inflammatory 
mediators can weaken the protective fibrous cap of the atheroma, possibly leading to 
thrombosis and the occurrence of acute coronary syndromes such as myocardial infarction 
[13]. All these aspects enhance the need to control inflammation in every single step of the 
disease progression, in order to prevent later problems. Therefore, inflammatory processes 
may be potential therapeutic targets to prevent or treat atherosclerosis and its subsequent 
diseases.  
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1.1.1. Lesion initiation and early progression of atherosclerosis 
 
Although the exact causes of atherosclerosis are still unclear, studies show that it initiates 
with subendothelial accumulation of apolipoprotein B-containing lipoproteins (apoB-LPs), 
responsible for carrying lipids, including cholesterol, around the body [14]. The retention is 
partially mediated by interaction with extracellular matrix (ECM) proteins, primarily 
proteoglycans [15]. ECM binding makes lipoproteins susceptible to modifications, such as 
oxidation [16]. This leads to the transiently activation of endothelial cells which secrete 
chemokines that promote recruitment of circulating monocytes [17]. 
The adhesion cascade of monocytes involves capture, selectin-dependent rolling, 
activation by endothelial surface-bound chemokines, integrin-mediated adhesion and 
transendothelial migration [18]. During this process, several adhesion molecules and 
chemokines play a crucial role, including E- and P-selectin, intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and tethered chemokines on the luminal 
surface of the endothelium [19, 20]. Notably, selectins interact with P-selectin glycoprotein 
ligand-1 (PSGL-1) expressed on monocytes allowing them to roll on the endothelium. Then, 
monocytes use lymphocyte function-associated antigen-1 (LFA-1), very late antigen-4 (VLA-4), 
macrophage-1-antigen (Mac-1) and their respective endothelial cell ligands, including vascular 
cell adhesion molecule (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), to slow 
rolling and form tighter adhesions [21]. Monocyte firm adhesion to the endothelium is 
coordinated by chemokines such as CCL2 and IL-8 [22]. Finally, firm adhesion of monocytes is 
followed by their entry into the subendothelial space - diapedesis [23]. In the intima, 
monocytes quickly differentiate into macrophages due to the production of colony stimulating 
factor (M-CSF) by vascular cells such as endothelial cells (EC) and smooth muscle cells (SMC) 
[24].  
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Figure 1- Lipoproteins retention, monocyte recruitment and foam cell formation (adapted from 
[25]). Monocytes use different chemokine–chemokine receptor pairs to infiltrate the intima, which is 
facilitated by endothelial adhesion molecules, including selectins ICAM1 and VCAM1. The recruited 
monocytes differentiate into macrophages in the intima, where take up native and modified (for 
example, oxidized) low-density lipoprotein (LDL) via macropinocytosis or scavenger receptor-mediated 
pathways (including via scavenger receptor A1 (SR-A1) and CD36), which results in the formation of the 
foam cells that are a hallmark of the atherosclerotic plaque. These foam cells secrete pro-inflammatory 
cytokines (including interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF)) and chemokines (such as 
chemokine (C-C motif) ligand 2 (CCL2)) that amplify the inflammatory response. 
 
1.1.2 Macrophages in the pathogenesis of atherosclerosis  
 
 Monocyte differentiation and macrophage polarization 
 
Under homoeostatic conditions, the majority of the organs, including the heart, contain a 
small population of resident macrophages [26, 27]. Upon a pro-inflammatory injury, an 
increased number of blood monocytes extravasated into the tissue and differentiate into M1 
macrophages (pro-inflammatory). In the following resolution phase, M1 macrophages are 
replaced by M2 macrophages (pro-resolution, pro-regeneration). Therefore, in response to 
inflammatory damage monocytes can extravasate into the heart and differentiate into M2 
macrophages, thus promoting cardiac repair and remodeling [28, 29]. 
Monocytes that arrive to atherosclerosis lesions differentiate into macrophages, which 
then can polarize towards different subsets, following a specific stimuli [30]. The first stage 
of differentiation is induced by macrophage colony stimulating factor (M-CSF) or granulocyte 
macrophage colony stimulating factor (GM-CSF), while the subsequent phenotypic polarization 
that macrophages adopt is dependent on the concentration of the various mediators that 
these cells are exposed to [24, 31, 32]. Nomenclature in the literature is not consistent, 
polarized macrophages are generally named as M1 (classically activated) or M2 (alternatively 
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activated) [33]. The M1 and M2 terms parallel the T helper cell th-1 and th-2 cytokines which 
drive macrophage polarization [33]. 
M1 macrophages are induced by the presence of granulocyte macrophage colony-
stimulating factor (GM-CSF) or Toll-like receptor (TLR) ligands [34]. The family of TLRs is the 
major and most extensively studied class of pattern recognition receptors (PRRs) and TLR2 
and TLR4 are described as crucial mediators of macrophage activation [35, 36]. 
TLRs exhibit leucine-rich repeats (LRR) motif in the ectodomain implicated in ligand 
recognition (such as lipopolysaccharides (LPS) by TLR4 or lipoproteins by TLR2), a 
transmembrane domain, and a cytoplasmic tail containing the Toll–IL‑1‑resistence (TIR)-
signaling domain [37, 38]. TLR signaling is initiated by ligand induced dimerization of 
receptors and recruitment of adaptor proteins to its TIR domain: myeloid differentiation 
primary-response protein 88 (MyD88), TIR domain-containing adaptor inducing IFN-β (TRIF), 
TIR domain- containing adaptor protein (TIRAP)/MyD88-adaptor-like (MAL) and TRIF-related 
adaptor molecule (TRAM) [39, 40]. Engagement of the signaling adaptor molecules activates 
downstream signaling pathways involving interactions between IL‑1R‑associated kinases 
(IRAKs) and the adaptor molecules TNF receptor-associated factors (TRAFs) that lead to the 
activation of the mitogen-activated protein kinases (MAPKs) JUN N-terminal kinase (JNK) and 
p38, and to the activation of transcription factors: nuclear factor‑κB (NF‑κB), interferon-
regulatory factors (IRFs), cyclic AMP-responsive element-binding protein (CREB) and activator 
protein 1 (AP1) [40–42] (Figure 2). TLR signaling finishes with the induction of pro-
inflammatory mediators such as tumor necrosis factor-α (TNF-α), IL -1β, IL-6, IL-12, IL-23, 
inducible nitric oxide synthase (iNOS) and monocyte chemoattractant protein (MCP)-1, also 
called CCL2, and in the case of the endosomal TLRs, the induction of type I interferon (IFN) 
[43, 44]. Moreover, M1 macrophages normally express increased levels of other surface 
molecules as CD86, CD80, MHC II, and iNOS [43].  
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Figure 2 – Toll-Like Receptors signaling pathways (adapted from [40]).  TLR signaling plays an 
essential role in the innate immune response. Recognition of pathogen-associated molecular patterns 
(PAMPs) activates TLR signaling leading to transcriptional activation of genes encoding for pro-
inflammatory cytokines, chemokines and co-stimulatory molecules. 
 
However, the inflammatory reaction is spatially and temporally counteracted by 
alternatively activated M2 macrophages, which display an anti-inflammatory phenotype and 
are involved in tissue remodeling and wound repair events. M2 macrophages are 
heterogeneous [45]. Mantovani et al. proposed the compartmentalization into three subtypes 
generated by different inflammatory and opsonic signals [43]. M2a macrophages are 
stimulated by IL-4/IL-13 and participate in tissue repair and extracellular matrix deposition; 
M2b macrophages result from activation with immune complexes (IC) and TLR agonists (like 
LPS) and release anti-inflammatory IL-10, as well as the pro-inflammatory cytokines TNF-α, 
IL-6 and IL-1, while also promoting Th-2 type adaptive immune responses with increased T-
cell IL-4 production and B-cell IgG class switching; M2c macrophages which are driven by IL-
10, TGF-β or glucocorticoid hormones and are characterized by high production of IL-10 
levels, decrease of pro-inflammatory cytokines limiting inflammation, and increase of debris-
cleaning activity [43, 46, 47]. Globally, M2 macrophages tend to produce high levels of anti-
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inflammatory products such as arginase-1, IL-10, transforming growth factor-β (TGF-β), 
scavenger receptors (SR) and mannose receptors (MR), and express transcription factors as 
Krüppel-like factor 4, peroxisome proliferator activated receptor-γ (PPARγ) and STAT6 in M2a 
macrophages and STAT3 in M2c macrophages [48–50]. 
 Macrophage phenotypes in atherosclerosis 
 
Macrophage heterogeneity is particularly important in atherosclerosis lesions, due to the 
opposing roles of M1 and M2 subtypes during inflammation. Plaque microenvironment is 
extremely rich in several molecules that can work as modulators of macrophage phenotype, 
such as oxidative modified lipids, lipoproteins, cytokines, chemokines and growth factors 
[51]. The total number of macrophages, as well as the presence of pro-inflammatory 
cytokines, increase with disease progression, a phenomenon associated with increased plaque 
vulnerability [52]. Consistent with this, M1 macrophages are shown to be the predominant 
population in the site most prone to plaque rupture, while in the fibrous cap regions, there 
are both M1 and M2 macrophages [53]. Thus, potential deleterious effects of M1 macrophages 
may be counteracted by protective pro-fibrotic and tissue repair effects of M2 macrophages 
in the fibrous cap, while the limited number of M2 macrophages cannot balance the M1-
mediated effects in the unstable plaque [53].  
Macrophages respond to oxLDL, cholesterol crystals, LPS and IFN-γ by polarizing towards 
M1 phenotype, expressing pro-inflammatory and pro-atherogenic profiles, which associates 
this subset to plaque vulnerability [54]; in turn, M2 macrophages display atheroprotective 
characteristics mainly because of the tissue remodeling capacity of M2a macrophages, primed 
by IL-4, and efferocytosis capacity of M2c macrophages, primed by IL-10 or TGF-β, which are 
responsible for the phagocytosis of apoptotic cells [55, 56]. More recently, additional plaque-
specific macrophage phenotypes have been identified: Mox, induced by oxidized 
phospholipids and exhibit reduced phagocytic capacity and anti-oxidant properties; Mhem and 
M(Hb), identified in areas of intraplaque hemorrhage and characterized by anti-inflammatory 
and atheroprotective profiles similar to M2 macrophages;  and M4, a novel human 
macrophage phenotype induced by platelet derived chemokine CXCL4, and reported to be 
irreversible and pro-atherogenic [52, 57]. Table 1 makes an overview of each macrophage 
subset characteristics described in vitro and their function in atherosclerosis.  
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Table 1 – Macrophages subsets characteristics described in vitro and functions in atherosclerosis. 
Phenotype Induction  Cell markers 
Cytokines and 
chemokines 
production 
Functions in 
atherosclerosis 
References 
M1 
IFN-γ, TNF-α, 
LPS, GM-CSF 
CD86, CD80, 
MHC II, TLR2, 
TLR4 and iNOS 
TNF-α, IL -1β, IL-6, 
IL-10low IL-12high,  
IL-23, iNOS, CCL2 
Th1 inflammatory 
response, 
atherogenesis, 
plaque rupture 
[34, 43, 44]  
M2a IL-4, IL-13 MR, IL1RN 
IL-10, TGF-β, 
CCL17, CCL22 
Tissue remodeling, 
atheroprotective  
[46, 58] 
M2b IC, TLR agonists 
MR, MHCII, 
CD86, IL-10high, 
IL-12low 
IL-6, IL-10high,  
IL-12low, TNF-α 
Immunoregulation [33] 
M2c 
IL-10, TGF-β, 
glucocorticoids 
MR, CD163 IL-10, TGF-β 
Efferocytosis, 
atheroprotective 
[55, 56] 
M4 CXCL4 
MR, MMP7, 
S100A8 
IL-6, TNF-α, MMP12 
Weak phagocytosis, 
minimal foam cell 
formation, pro-
inflammatory 
[59, 60] 
Mox oxPL 
HMOX-1, Nrf2, 
Srxn1, Txnrd1 
IL-1β, IL-10 
Weak phagocytosis, 
proatherogenic 
[61] 
M(Hb) 
Hemoglobin/ 
haptoglobin 
MR, CD163 
ABCA1, ABCG1, 
LXR-α 
Hemoglobin 
clearance, high 
cholesterol efflux, 
atheroprotective 
[62–64] 
Mhem Heme ATF1, CD163 LXR-β 
Erytrophagocytosis, 
atheroprotective 
[62, 65, 66] 
Abbreviations: ABC, ATP-binding cassette transporter; ATF1, activating transcription factor 1; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C 
motif) ligand; HMOX-1, heme oxygenase-1; IL1RN, interleukin 1 receptor antagonist; LXR, liver X receptor; MHCII, major histocompatibility complex class II; 
MMP, matrix metalloproteinase; Nrf2, nuclear erythroid-2 related factor; oxPL, oxidized phospholipids; Srxn1, sulforedoxin-1; S100A8, S100 calcium-binding 
protein A8; Txnrd1, thioredoxin reductase 1; For the other abbreviations refer to the text. 
 
1.1.3 Foam cell formation 
 
In atherosclerosis, macrophages can accumulate membrane-bound lipid droplets in their 
cytoplasm. These lipid-loaded cells are called “foam cells” and their formation begins with 
the ingestion and processing of accumulated apoB-LPs [11]. This event is regulated by the 
balance between the uptake of the modified LDL and efflux of cholesterol and other lipids 
[67].  
This uptake is mediated by CD36, SR-A1, oxidized LDL receptor-1 (LOX-1), TLR4/MD-2, 
TLR2 and a number of other receptors (Figure 3). Unmodified LDL can also enter in 
macrophages by micro- and micropinocytosis [31, 68–73].  
To control membrane levels of sterols, cells essentially employ a feedback system that is 
mainly regulated at the transcriptional level by endoplasmic reticulum (ER)-bound sterol 
regulatory element-binding proteins (SREBPs) [74]. Under low cholesterol levels, SREBPs are 
transported to the Golgi complex and proteolytically processed. The generated active 
peptides may enter to the nucleus and activate the transcription of target genes. SREBP2 and 
SREBP1a activate the transcription of cholesterol-related genes expression including 3-
hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr) and low-density lipoprotein receptor 
(Ldlr), while SREBP1c enhances the expression of fatty acid metabolism-related genes, such 
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as fatty acid synthase (Fas) [74–76]. Under high cholesterol levels, SREBP is unable to exit the 
endoplasmic reticulum and, consequently, transcription of target genes is reduced [77]. 
The excess of cholesterol, oxysterols and phospholipids, which accumulates in 
macrophages and is not degraded, can be removed by ATP-binding cassette (ABC) transporters 
in a process called reverse cholesterol transport [78]. ABCA1 and ABCG1 are upregulated 
during macrophage differentiation [79, 80]. ABCA1 efflux cholesterol to poor-lipidated APOA1 
[81], while ABCG1 is mostly involved in the lipidation of mature HDL particles [82]. 
Peroxisome proliferator–activated receptor-γ (PPAR-γ) and liver X receptor (LXR) agonists 
regulate macrophage foam cell formation in atherogenesis [83–85]. PPAR-γ agonists can 
inhibit foam cell formation in vivo through ABCA1-dependent [86] and ABCA1-independent 
pathways [87]. Activation of PPAR-γ reduces cholesterol esterification and induces expression 
of ABCG1 [88]. LXR activation in macrophages reduces foam cell formation via induction of 
both ABCA1 and ABCG1 [89, 90]. 
 
 
 
 
Figure 3 - Signaling pathways in macrophages following cholesterol uptake (adapted from [67]). 
Various pro- and anti-inflammatory forces act on macrophages in atherosclerotic lesions, leading to 
activation of downstream cascades, such as the inflammasome, SR/TLR cooperative signaling, 
endoplasmic reticulum stress, expression of the sterol responsive network, and efflux of cholesterol via 
ABCA1 and ABCG1 transporters.  
 
Foam cells are important sources of chemokines (MCP-1), cytokines (TNF, IL, and IFN), 
enzymes (metalloproteases, cysteine and serine proteases), growth factors (platelet-derived 
growth factor, VEGF, and IGF), bioactive lipids and angiogenic factors. Together with proteins 
secreted by T cells and pro-inflammatory cytokines secreted by M1 macrophages, the 
inflammatory process is perpetuated, which will promote migration of vascular smooth 
muscle cells (VSMCs) into the intima and well as their proliferation and secretion of pro-
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fibrotic agents, but also migration of endothelial cells, contributing the resulting fibrous cap 
formation [73, 91] .  
M2 macrophages are characterized by the expression of scavenger receptors, which play a 
major role in the clearance of oxLDL, especially CD36 [72]. These are found to bind and 
internalize modified forms of LDL through mechanisms that are not inhibited by cellular 
cholesterol content, and these are likely responsible for macrophage cholesterol 
accumulation [92]. M1 macrophages express TLRs on their surface, especially TLR2 and TLR4, 
which are known to be part of modified LDL uptake [36, 93, 94]. For example, complex 
TLR4/MD-2 is described to recognize minimally oxidized LDL and induce membrane ruffling 
and robust micropinocytosis, resulting in uptake of native and modified LDL and foam cell 
formation [95]. Consistent with this, other studies have demonstrated conjugated interactions 
between TLRs and other proteins such as CD14 and CD36 to recognize modified lipids and 
promote inflammatory gene expression [96–100]. Thus, macrophages recognize modified 
lipoproteins through TLR2 and TLR4. Scavenger receptor CD36, which binds oxLDL, forms 
complexes with TLR heterodimers and in turn mediates pro-inflammatory effects of modified 
lipoproteins. Activation of TLR by proatherogenic modified lipoproteins leads to the activation 
of pro-inflammatory signaling pathways involving NF-κB, MAPKs, and reactive oxygen species 
(ROS) dependent signaling [101]. Expression of pro-inflammatory genes switches macrophage 
phenotype towards M1. In addition, oxLDL-mediated stimulation of CD36 leads to the 
activation of inflammasome that further aggravates vascular inflammation [101]. Michelsen et 
al. showed that mutation in either the adaptor molecule MyD88 or its upstream receptor TLR4 
exhibit reduced aortic atherosclerosis, plaque lipid content and plaque macrophage 
infiltration [100]. They further provide evidence suggesting that MyD88 deficiency leads to 
decreased levels of the circulating pro-inflammatory molecules IL-12p40 and/or monocyte 
chemoattractant protein 1 (MCP-1/CCL2) [100, 102].  
Studies regarding the ability of macrophages with different polarization status to uptake 
lipids are not consistent [103]. However, the increase of pro-inflammatory environment may 
drive monocyte to macrophage differentiation towards M1 phenotype. Accordingly, this would 
account for the reported absence of M2 foam cells in advanced human lesions, or their 
location distant from the core [104, 105].  
 
1.1.4 Macrophages in advanced atherosclerosis 
 
Atherosclerosis can be considered a nonresolving inflammatory condition. As 
atherosclerotic lesions progresses, monocytes continue to enter plaques and differentiate into 
macrophages [25]. Consequently, in advanced lesions, a pro-inflammatory environment 
ensues with greater levels of Th1 cytokines (such IFN-γ) than Th2 cytokines. Macrophages 
contribute to the plaque morphology, thinning the fibrous cap, and necrotic core, which can 
lead to increased pro-inflammatory responses and further apoptotic signals for SMCs, ECs and 
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leukocytes within the plaques [106, 107]. Furthermore, apoptotic macrophage foam cells also 
contribute to this scenario [108].  
One important function of macrophages is the clearance of apoptotic cells in a process 
called efferocytosis. Efferocytosis is primarily a function of alternatively activated (M2) 
macrophages [109]. As macrophages engulf oxidized lipids and other cellular debris in the 
arterial wall during early stages of atherogenesis, many of these macrophages undergo 
apoptosis [108]. In early atherogenesis, macrophage apoptosis is associated with reduced 
atherosclerosis progression [110]. Efficient efferocytosis of apoptotic macrophages results in 
at least three critical protective effects: (1) it clears the cells before membrane damage, 
preventing extracellular leakage of toxic intracellular material; (2) it triggers an IL-10- and 
TGFβ-mediated anti-inflammatory response in the efferocytes; and (3) it promotes survival of 
the efferocytes themselves so that they do not succumb to potentially toxic factors of 
apoptotic cells [25, 111]. Therefore, macrophage apoptosis by itself will not trigger plaque 
necrosis. Rather, uptake of excessive apoptotic cells by macrophage effecrocytes induces 
endoplasmic reticulum stress and the unfolded protein pathway response, which increases the 
expression of a pro-apoptotic protein, called CEBP homologous protein (CHOP) [112]. As 
atherosclerosis progresses, efferocytosis is thought to become impaired [113]. With the 
plaque adopting an increasingly inflammatory environment, macrophage are differentiated 
towards the M1 form and consequently, M1 foam cells predominate. As M1 macrophages have 
low efferocytosis capability, and there is a decreasing number of M2 efferocytes, apoptotic 
foam cells undergo secondary necrosis [114]. Thus, failure of efferocytosis leads to a 
secondary necrosis, not only by macrophages which release their cellular contents, including 
debris, oxidized lipids and pro-inflammatory mediators, but also by smooth muscle cell-
derived foam cells, amplifying the inflammatory response and leading to the development of 
a necrotic core and accumulation of extracellular cholesterol in the plaque [115]. At this 
stage, macrophages also secrete matrix metalloproteinases (MMPs) which promote 
neovascularization and are capable of degrading the collagen produced by SMCs, reducing the 
strength of the plaque’s protective fibrous cap, rendering that cap thin, weak and susceptible 
to rupture [116]. When plaque ruptures, blood components are exposed to tissue factor, the 
major pro-coagulant and trigger of thrombosis, which is also produced by the macrophages 
[13], initiating coagulation, recruitment of platelets and formation of a thrombus, which 
narrows the arterial passage, restricting blood flow (Figure 4). These events are regulated by 
the inflammatory mediators, which demonstrate an essential link between arterial 
inflammation and thrombosis.  
Thus, to prevent atherosclerosis progression and severity it is important to get a balance 
between apoptosis, efferocytosis and secondary necrosis. Many possibilities have been studied 
but, given the association of M1 macrophage with plaque instability, decreasing the levels of 
these pro-inflammatory macrophages in the plaque is a promising avenue for plaque 
stabilization.  Modulation of macrophage phenotype in the arterial wall during atherogenesis, 
which would lead to the accumulation of poorly phagocytic macrophages, is being considered 
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a key factor in atherosclerosis research. As macrophages show a high degree of plasticity in 
early and advanced atherosclerotic plaques, with the ability to undergo dynamic transition 
between M1 phenotype and M2 phenotype, we hypothesize that modulating the balance 
between M2 macrophages (characterized by high IL-10 production) and pro-inflammatory M1 
macrophages will increase the efficient clearance of early apoptotic cells and decrease the 
progression of the disease. To achieve this goal, we propose to use microRNAs (miRNAs) that 
have emerged as therapeutic targets for several biological mechanisms, including macrophage 
polarization. In cardiovascular diseases dysregulation of miRNAs has been linked to the 
development and progression of the pathology [117, 118]. The forced expression or 
suppression of a single miRNA is sufficient to cause or alleviate pathological changes. In the 
next section this will be discussed in detail. 
 
 
 
 
Figure 4 - Forces in the advanced lesion that destabilize the atherosclerotic plaque (adapted from 
[67]). (1) Macrophage foam cells undergo apoptosis as a result of prolonged endoplasmic reticulum 
stress and other stimuli; (2) apoptotic cells are not effectively cleared by advanced lesional 
macrophages (defective efferocytosis); (3) accumulation of apoptotic cells induces secondary necrosis 
and (4) contributes to the formation of a necrotic core. (5) Smooth muscle cell death and protease 
degradation of extracellular matrix weakens the fibrous cap, making it susceptible to rupture. (6) 
Exposure of the thrombogenic material of the lesion causes platelet aggregation and thrombus 
formation. 
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1.2 MicroRNAs  
 
1.2.1 MicroRNA biogenesis 
 
MicroRNAs (miRNAs) are single-stranded RNAs typically 15-25 nucleotides long, which can 
regulate gene expression at a post-transcriptional level and play a central role in tissue 
development and in the pathogenesis of several diseases [119]. miRNAs originate from long 
RNAs called primary miRNAs that are regulated by conventional transcription factors and 
transcribed by RNA polymerase II [120]. Primary miRNAs are hundreds to thousands of 
nucleotides long and are processed in the nucleus into an approximately 70- to 100-nucleotide 
hairpin-shaped precursor miRNA, by the RNase III enzyme Drosha and the double-stranded 
RNA binding protein DGCR8. Then, the miRNA precursor is transported into the cytoplasm by 
the nuclear export factor exportin 5 and further processed into an 15- to 25-nucleotide 
double-stranded RNA by the RNase III enzyme Dicer. This duplex miRNA is then incorporated 
into the RNA-induced silencing complex. Subsequently, one strand of the mature miRNA is 
retained in the RNA-induced silencing complex, whereas the other strand is often degraded 
(Figure 5) [121]. Once loaded into the RNA-induced silencing complex, the mature miRNA 
associates with target mRNAs and acts as a negative regulator of gene expression by 
promoting translation inhibition or mRNA degradation. In mammals, the predominant 
mechanism is translation inhibition; however, targeted genes that are strongly downregulated 
at the protein level often show reduced mRNA levels [122], suggesting that mRNA 
destabilization gives also a major contribution to gene silencing. 
A mature miRNA typically regulates gene expression via an association with the 3’ 
untranslated region (UTR) of an mRNA with complementary sequence, although emerging 
evidence suggests that miRNAs may also target 5’UTRs or exons and may potentially undergo 
base pairing with regulatory DNA sequences to regulate transcription [121]. Once miRNA bind 
to a 3’ UTR, the degree of mRNA degradation and/or translational repression is affected by 
multiple mechanisms, including the overall complementarity between the miRNA and target 
mRNA, the secondary structure of the adjacent sequences, the distance of the miRNA binding 
site to the coding sequence of the mRNA, and the number of target sites within the 3’ UTR 
[123]. Complementarity between mRNA and nucleotides 2 through 8 of the miRNA, called the 
“seed” region, appears to be essential for 3’ UTR identification. Therefore, miRNAs with high 
sequence homology and identical seed region are commonly grouped into miRNA families that 
are likely to target similar sets of mRNAs [124]. 
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Figure 5 – Mechanism of microRNA biogenesis (adapted from [125]). In the nucleus, a primary 
microRNA is transcribed from the genome and processed by Drosha. Then, the precursor microRNA is 
exported to the cytoplasm where it is further processed by Dicer. Mature microRNA is then incorporated 
into RISC complex. 
 
Accordingly to mirBase (www.mirbase.org), around 2000 miRNAs are predicted in the 
human genome, each one of them could potentially target several mRNAs. On the other hand, 
most 3’ UTRs contain potential binding sites for a large number of individual miRNAs, allowing 
redundancy or cooperative interactions between various seemingly unrelated miRNAs [120]. 
Furthermore, the targets of many miRNAs can modulate the expression of additional miRNAs 
or groups of miRNAs, generating positive or negative feedback loops. Finally, miRNA 
maturation seems to be post-transcriptionally regulated in a sequence-specific manner, 
potentially explaining why genetically clustered and cotranscribed miRNAs are often 
expressed at different levels [126]. 
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During the last decade nomenclature of the miRNAs has evolved. For that reason, a brief 
description of the most commonly used nomenclature is presented in Table 2. 
 
Table 2 - Nomenclature of microRNAs. (adapted from [124]) 
Nomenclature format Description 
mir or miR Genes that encode miRNAs, primary transcripts of miRNAs, and stem-
loop precursor miRNAs are all named using the italicised prefix ‘mir’. 
Mature miRNAs are named using the non-italicised prefix ‘miR’. 
mir-X or miR-X With the exception of a few early miRNAs, miRNAs are sequentially 
assigned unique identifying numbers, depending on when they are first 
published, for example, mir-31 or miR-31. 
mir-Xa, mir-Xb, … Similar miRNA sequences within a species are distinguished by a lettered 
suffix, for example, mir-181a and mir-181b. However, this does not 
imply shared targets or functions. 
mir-X-1, mir-X-2, … Identical miRNA sequences within a species are distinguished by a 
numerical suffix, for example, mir-7-1 (chromosome 9), mir-7-2 
(chromosome 15) and mir-7-3 (chromosome 19), can all produce 
identical mature miRNAs. 
miR-X-5p or miR-X-3p The latest convention is to name mature miRNAs by the arm of the pre-
miRNA from which they are derived, regardless of their abundance— 
those from the 5’ arm are named miR-X-5p and those from the 3’ arm as 
miR-X-3p. 
has-miR-X, mo-miR-X, … All of the above naming conventions can be preceded by a three-letter 
code which identifies the species the miRNA is from, for example, 
hsa=homo sapiens (human); rno=rattus norvegicus (rat). 
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1.2.2 MicroRNAs and macrophage phenotypes 
 
miRNAs do not encode peptides; instead, those non-coding RNAs emerged as regulators of 
the expression of proteins encoded by their mRNA targets. Since the initial findings, many 
studies have shown that miRNAs are indeed meaningful regulators of cellular function in 
different tissues/organs [127].  From the perspective of inflammatory responses, miRNAs have 
been shown to affect directly the magnitude of the response, by targeting proteins involved 
in modulation of inflammation [125]. Furthermore, several studies reported a crucial role of 
miRNAs in the control of gene expression during macrophage polarization [128, 129]. On one 
hand, miRNAs regulate macrophage polarization acting as posttranscriptional inhibitors; on 
the other hand, miRNA levels are differently expressed in M1 and M2 phenotypes [126, 128].  
miR-155 is one of the miRNA most described to be associated to M1 macrophages profile 
and pro-inflammatory events.  O'Connell et al. recently observed that stimulation of 
macrophages with TLR2, TLR3, TLR4 and TLR9 ligands remarkably upregulated the expression 
of miR-155 [130]. Such an elevation of miR-155 was hampered by the knockdown of MyD88 
and TRIF, two factors known to activate the NF-κB signalling [130]. Moreover, the use of an 
JNK inhibitor diminished the upregulation of miR-155 and production of TNF-α, suggesting 
that miR-155-mediated activation of M1 polarization are due to induction of the JNK pathway 
[130]. Other findings revealed that miR-155 targets and downregulates SHIP1 and SOCS1, 
leading to increased activation of AKT and IFN response genes [131, 132]. Another miRNA 
reported to augment classical activation of macrophages is miR-127 [133]. Inhibition of miR-
127 expression by antagonist suppressed the expression of M1 signature genes and promoted 
transcription of M2 marker genes [133].  
Conversely, there are miRNAs overexpressed on M2 macrophages, suggesting that these 
promote M2 macrophage polarization [134]. Overexpression of miR-125a-5p has been 
associated to the reduction of M1 profile induced by LPS and to the promotion of M2 profile 
induced by IL-4. miR-125a-5p targets KLF13, a transcriptional factor that has an important 
role on T lymphocyte activation and inflammation [135]. Several reports also found that 
miRNA let-7c regulates macrophage polarization by promoting M2 phenotype expression and 
inhibiting M1 phenotype, by targeting C/EBP-δ [136]. miR-124 is also described to modulate 
LPS-induced cytokine production in macrophages by targeting signal transducer and activator 
of transcription 3 (STAT3) decreasing IL-6 production and TNF-α converting enzyme (TACE) 
reducing TNF-α release, which suggest an anti-inflammatory role for this miRNA [137]. 
Moreover, other miRNAs are known to be differently expressed in M1 versus M2 
macrophages phenotype, as miR-181a, miR-204-5p and miR-451 that are upregulated, and 
miR-146a-3p, miR-143-3p and miR-145-5p that are downregulated in M1 macrophages, 
suggesting a key role on regulation of inflammation [128, 129]. 
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1.2.3 MicroRNAs in cardiovascular diseases 
 
The involvement of miRNAs in the pathological process of the cardiovascular system has 
recently been described. Research on miRNAs in cardiovascular diseases is a rapidly evolving 
field.  Recent studies have demonstrated that miRNAs are aberrantly expressed in the 
cardiovascular system under some pathological conditions [118]. Gain- and loss-of-function 
studies using in vitro and in vivo models have revealed distinct roles for specific miRNAs in 
cardiovascular development and physiological function.  
miR-1 and miR-133 are two widely conserved miRNAs derived from a common precursor 
transcript that have been described to display cardiac- and skeletal-muscle specific 
expression during cardiac development [138–143]. In addition, other miRNAs have been 
associated to several CVDs, as cardiac hypertrophy, myocardial infarction and cardiac fibrosis 
[118].   
miR-21, miR-23a and miR-208 have often been found to be upregulated in hypertrophy, 
whereas miR-133 has often been found to be downregulated. Sayed et al. proposed that an 
increase in miR-21 enhances the formation of various types of cellular protrusions through 
direct targeting and down-regulating of SPRY2, an inhibitor of branching morphogenesis and 
neurite outgrowths [144]. In turn, Lin et al. reported that miR-23a is a pro-hypertrophic 
miRNA, and its expression is regulated by the transcription factor, nuclear factor of activated 
T cells (NFATc3) [145]. Also, miR-208 is associated to cardiac hypertrophy as the 
overexpression of this miRNA in the heart was sufficient to induce hypertrophic growth in 
mice, which resulted in pronounced repression of the miR-208 regulatory targets thyroid 
hormone–associated protein 1 and myostatin, two negative regulators of muscle growth and 
hypertrophy [146, 147]. Conversely, Carè et al. observed that overexpression of miR-133 
inhibited cardiac hypertrophy [148]. 
Moreover, in acute myocardial infarction (AMI) several miRNAs are proposed to be 
involved in the cardiomyocyte death/apoptosis. MiR-1 is thought to be involved in the 
promotion of cell apoptotic events as it was significantly increased on apoptosis induced by 
oxidative stress in H9c2 rat ventricular cells [149]. In addition, miR-1 is also associated with 
the cell death pathway by inhibiting the translation of insulin like growth factor 1 (IGF)-1 
[150]. In turn, Dong et al. identified that miR-21 had a protective effect on ischemia-induced 
cell apoptosis [151]. The protective effect of miR-21 against ischemia-induced cardiac 
myocyte damage was further confirmed in vivo by decreased cell apoptosis in the border and 
infarcted areas of the infarcted rat hearts after treatment with an adenovirus expressing miR-
21 [151]. MiR-199a was reported to be downregulated in cardiac myocytes on a decline in 
oxygen tension. This reduction is required for the rapid upregulation of its target, hypoxia-
inducible factor (Hif)-1alpha. Replenishing miR-199a during hypoxia inhibits Hif-1alpha 
expression and its stabilization of p53 and, thus, reduces apoptosis [152]. 
In cardiac fibrosis, an important miRNA family has emerged as inhibitor of fibrosis in the 
border zone of the infarcted area. miR-29, which is fibroblast enriched, targets mRNAs 
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encoding ECM-related proteins involved in fibrosis, including multiple collagens, fibrillins and 
elastin. MiR-29 is dramatically repressed in the border zone flanking the infracted area in the 
mouse model of AMI [153]. Downregulation of miR-29 would be predicted to counter the 
repression of these mRNAs and enhance the fibrotic responses. 
Regarding to atherosclerosis, several studies have been performed in order to better 
understand the role of miRNAs in key steps of the disease initiation and progression as 
endothelial dysfunction, cholesterol homeostasis and reverse cholesterol transport, plaque 
development and plaque rupture [117].  
As detailed in section 1.1.1, during endothelial dysfunction several endothelial adhesion 
molecules (e.g. ICAM-1, VCAM-1, E-selectin) and chemotactic factors are overexpressed, 
allowing the recruitment and entry of monocytes and other leukocytes into the intima. miR-
10a is one of the miRNAs that is thought to be involved in endothelial dysfunction as it 
inhibits a number of pro-inflammatory genes in ECs, including VCAM-1 and E-selectin, and the 
NF-κB pathway [154]. miR-126, miR-31 and miR-17-3p also regulate vascular inflammation by 
controlling the expression of the adhesion molecules [155, 156]. In addition, ECs transfected 
with miR-155 mimic were shown to be less migratory compared with control ECs [157]. 
Relatively to endothelial aging, miR-217 and miR-34a are described to promote EC senescence 
[158, 159], whereas Vasa-Nicotera et al. suggested miR-146a as a target of the NOX4, a 
protein implicated in cell senescence and aging [160]. 
Cholesterol homeostasis is also regulated by miRNAs. A recent study identified miR-33a 
and miR-33b as intronic miRNAs located within the Srebp2 and Srebp1 genes respectively 
[161]. Both miRNAs are co-transcribed with their host genes and regulate cholesterol and 
fatty acid metabolism [162, 163]. Also miR-122 is involved in the regulation of cholesterol 
metabolism. Élmen et al. showed that inhibition of miR-122 levels in the liver results in a 
significant reduction of plasma cholesterol levels in mice and non-human primates [164].  
Interestingly, miR-33 is also described to have a crucial role in the inhibition of reverse 
cholesterol transport, also known as cholesterol efflux. This miRNA is known to target ABCA1 
and ABCG1 in vivo. Rayner et al. showed that it inhibits cellular cholesterol efflux to APOA1 
and mature HDL and reduces the circulating HDL-cholesterol (HDL-C) levels in mice and non-
human primates [161]. Importantly, genetic deletion of miR-33 in mice increases plasma HDL-
C levels and reduces the progression of atherosclerosis [165]. As ABCA1 has a very long 3’UTR 
chain, several reports have found multiple miRNAs that can regulate this transporter 
including, miR-26, miR27-a/b, and miR-758, among others [166–168]. 
Inside the intima, monocytes/macrophages and VSMCs are loaded with modified LDLs 
through scavenger receptors, TLRs and LDL receptors giving rise to foam cells and activating 
VSMCs, which then lead to plaque development. Lipid uptake and inflammatory responses in 
monocytes/macrophages are regulated by miRNAs such as miR-155 or miR-125a-5p. miR-125a-
5p was found to mediate lipid uptake and to decrease the secretion of some inflammatory 
cytokines (IL-2, IL-6, TNF-α) in oxLDL-stimulated monocyte-derived macrophages [169]. 
However, data regarding miR-155 is ambiguous since there are studies associating this 
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microRNA to atherosclerosis progression while others emphasize its role in the prevention of 
disease development [170, 171].  
The evolution from fatty streaks to a fibrous atheroma is also promoted by VSMCs 
proliferation in the neointima. VSMC differentiation and apoptosis is regulated by 
transforming growth factor-β (TGF-β), which is a known target of miR-26a [172]. 
Metalloproteinases (MMP) expression, such as MMP2/9, controls VSMCs proliferation. MMPs 
expression is regulated by DNMT3b, a methyltransferase enzyme that silences the expression 
of these genes [172]. Interestingly, Chen et al. showed that miR-29b is upregulated in VSMCs 
treated with ox- LDLs and targets MMP2 thereby reducing VSMC migration [173].  
Wang et al. showed that miR-195 inhibits VSMCs proliferation and migration and reduces 
the synthesis of IL-1β, IL-6, and IL-8 [174].  Using bioinformatics prediction and experimental 
studies, the authors showed that miR-195 could repress the expression levels of Cdc42, 
CCND1, and FGF1 genes, which are involved in cell cycle control, migration, and 
proliferation. Moreover, the authors found that the miR-195 introduced by adenovirus 
substantially reduced neointimal formation in a balloon-injured carotid artery, which 
confirms the therapeutic potential of this miRNA [174]. 
As the intima wall thickens, the oxygen effective diffusion from the lumen becomes more 
difficult and vasa vasorum proliferates in the inner layers of the vessel wall. The promotion of 
neovessels formation has been linked to cholesterol-loaded macrophages which produce 
cytokines responsible for this proliferation [175, 176]. In advanced lesions, the 
microenvironment becomes enriched in pro-inflammatory, pro-oxidant and proteolytic 
factors, as the neoangiogenesis drive more blood components, specially monocytes and 
macrophages, to the plaque. This pro-inflammatory scenario has been studied in order to 
understand miRNAs role in this context. miR-146a and miR-21 were described to target TLR4, 
negatively regulating LPS-induced lipid accumulation and inflammatory responses in 
macrophages by the TLR4-NF-κB pathway [177, 178]. The loss of collagen, endothelial and 
VSMCs due to the high expression of proteolytic enzymes and apoptosis also favours plaque 
instability and further rupture. At this regard, miR-29 inhibits the expression of Col3A1, and 
elastin (ELN), thus reducing vascular integrity [153, 179]. miR-365 can function as a pro-
thrombotic factor by stimulating endothelial apoptosis [180], whereas miR-21 protects VSMCs 
from H2O2-induced apoptosis [181].  
Figure 6 stresses the relationship between miRNAs and atherosclerosis, by showing their 
effect on the three main types of cell involved in the pathogenesis of the disease.  
In summary, studies have unravelled the role of miRNAs in inflammation and in 
atherosclerosis development and progression. Consequently, miRNAs are potential 
therapeutic targets.  In this context, modulation of macrophages inflammatory response using 
miRNAs may lead to the development of novel therapeutic approaches for arthrosclerosis and 
cardiovascular diseases.
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Figure 6 - MicroRNAs in atherosclerosis. (A) Some of the relevant factors involved in atherosclerosis development and plaque rupture: cell types (leucocytes/macrophages, 
SMCs, ECs, RBCs, platelets), cholesterol particles (VLDL, LDL and HDL), collagen, necrotic and lipid core. (B–D) Systematization of microRNAs and microRNAs-targets in the 
most relevant cell types involved in atherosclerosis.  
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1.3 Objectives 
 
The aim of this work was to promote inflammation resolution by reducing M1-like and/or 
enhancing M2-like macrophage polarization, using miRNAs.  
Specifically, we intended to: 
1. Investigate miR-195 for its potential to modulate the polarization of human primary 
macrophages; 
2.  Determine potential miR-195 targets involved in inflammatory pathways by silico 
predictions; 
3. Analyze the biological effect of miR-195 on macrophage activation and differentiation 
and unravel the downstream molecular targets; 
4. Evaluate the functional impact of miRNA delivery to macrophages regarding their 
interaction with smooth muscle cells, namely by inducing alterations in their migratory 
profile. 
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Chapter 2 
Materials and Methods 
2.1 Cell culture 
 
2.1.1 Human monocyte isolation, differentiation and polarization  
 
Human primary monocytes were obtained from healthy blood donors buffy coats (BC), 
kindly donated by Serviço de Hemoterapia, Centro Hospitalar de São João (CHSJ) - Informed 
consent was obtained from all subjects before blood donation. RosetteSep human monocyte 
enrichment isolation kit (StemCell Technologies) was used, according to Oliveira et al. [203]. 
Firstly, BC were transferred to 50 ml tubes and centrifuged at room temperature (RT) for 20 
minutes (min) at 1200 g, without active acceleration or brake (Centrifuge 5810/ 5810 R, 
Eppendorf). Blood components were separated into three fractions, namely red blood cells 
(RBCs) on the top, peripheral blood mononuclear cells (PBMCs) in the thin middle layer, and 
plasma on top. PBMCs were collected, together with RBCs (approximately 3 mL) necessary to 
the formation of immunorosettes, and incubated with RosetteSep human monocyte 
enrichment isolation kit (67 µL/mL) for 20 min in a horizontal shaker. The mixture was 
diluted at a 1:1 ratio with 2% fetal bovine serum (FBS, Lonza) in PBS, gently layered over 
Histopaque-1077 (Sigma) to avoid mixture and then centrifuged as previously. The enriched 
monocyte layer was carefully collected, washed with 45 ml PBS, followed by centrifugation at 
100 g for 17 min with maximum acceleration and brake. Finally, the pellet was resuspended 
in complete culture medium [RPMI 1640 (Life Technologies) supplemented with 10 % FBS and 
1 % penicillin streptomycin (P/S) (Invitrogen) and Glutamax (Invitrogen)]. Cell count was 
performed in an optical microscope (Compact inverted microscope CKX41, Olympus) using a 
Neubauer chamber with trypan blue dye (Sigma) – exclusion assay. Finally, 0,5 x 106 cells per 
well were plated on top of sterile 13 mm glass coverslips in 24-well plates and cultured in a 
humidified 37ºC/5% CO2 incubator (Figure 7).  
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Figure 7 - Monocyte isolation from human buffy coats using RosetteSep. PBMCs and RBCs are 
incubated with RosetteSep Human Monocyte Enrichment cocktail that is designed to separate monocytes 
from other blood cells, by negative selection. It binds cell surface antigens on human hematopoietic 
cells, except monocytes, crosslinking unwanted cells with RBCs in immunorosettes that pellet along with 
the free RBCs when centrifuged over a density medium such as Histopaque. Following centrifugation, 
monocytes were collected, washed and cultured in vitro. 
 
Primary human monocytes were allowed to differentiate into macrophages. Cell culture 
media was carefully changed at day 7, ensuring minimum cell disturbance and incubated for 
additional 3 days. At day 10, macrophage polarization was induced. For pro-inflammatory M1 
stimuli, cells were treated with 10 ng/mL lipopolysaccharide (LPS), while for anti-
inflammatory M2c stimuli, cells were treated with 10 ng/mL interleukine-10 (IL-10) and 
incubated for additional 3 days (Figure 8). 
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Figure 8 - Monocyte/macrophage in vitro culture and polarization. At day 0 monocytes were isolated 
from human buffy coats using RosetteSep and allowed to differentiate for 10 days. Medium was changed 
at day 7. Macrophage polarization was induced with 10 ng/mL of LPS or 10 ng/mL of IL-10 for M1 and 
M2c phenotypes, respectively. Cells were harvested 3 days after polarization, at day 13 of culture, and 
stained for flow cytometry or processed for RNA extraction. 
 
2.1.2 THP-1 culture, differentiation and polarization 
 
THP-1 monocytic cells were cultured in complete RPMI 1640 medium supplemented with 
10% FBS + 1% P/S in an incubator at 37ºC/5% CO2. In order to induce a macrophage-like 
phenotype, cells were plated in 24 well plates (0.250 x 106 cells per well) with complete RPMI 
1640 medium containing 100 ng/mL of phorbol 12-myristate 13-acetate (PMA) and allowed to 
differentiate for 48h. Adherent cells were then rested in culture medium without PMA for 24 
h to obtain the resting state of macrophages. For polarization, cells were stimulated with 100 
ng/mL LPS + 20 ng/mL IFN-γ (Sigma). 
 
2.1.3 Human umbilical artery smooth muscle cells  
 
Human umbilical artery smooth muscle cells (HUASMC), kindly donated by Dr. Elisa Cairrão 
from Centro de Investigação em Ciências da Saúde - Universidade da Beira Interior, were 
cultured in Dulbecco's modified Eagle's F12 (DMEM-F12) supplemented with 5% FBS, epidermal 
growth factor (EGF, 5 μg/ml), fibroblast growth factor (FGF, 0.5 ng/ml), heparin (2 μg/ml) 
(all from Immunotools), and insulin (5 μg/ml) (Sigma). The cells were plated in T75 flasks 
previously coated with collagen and cultured in a humidified 37ºC/5% CO2 incubator. The 
culture medium was changed every 2–3 days. Confluent cells were detached using trypsin and 
subcultures were performed until the eight passage. 
2.2 Transfections 
 
Differentiated THP-1 macrophages were transfected with Pre-miR miRNA Precursor miR-
195-5p or with Pre-miR miRNA Precursor Negative Control (Scrambled - SCR) (Life 
Technologies) using Lipofectamine 2000 transfection reagent (Invitrogen) or HiPerFect 
Transfection Reagent (Qiagen). Briefly, miRNA mimics or SCR control were diluted in Opti-
Day 0 Day 10 
Monocyte isolation 
from human buffy 
coats 
Macrophage 
polarization  
(10 ng/ml LPS 
or IL-10) 
Day 13 Day 7 
Change cell 
culture media 
Cell harvest  
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MEM. A second reaction was prepared by incubating Lipofectamine 2000 in Opti-MEM for 5 min 
at room temperature (2 µL Lipofectamine 2000 per 50 µL Opti-MEM). Lipofectamine 2000 was 
then added to miRNA mimics and incubated for 20 min at room temperature to allow 
formation of complexes. Finally, solution was added to the cells with RPMI media without 
antibiotics. Final miRNA mimics concentration was 50 nM per well. 
2.3 Flow cytometry 
 
Differentiated and polarized macrophages derived from primary monocytes or THP-1 cells 
were harvested with 5mM EDTA-PBS and centrifuged at 300 g for 5 min, at 4ºC. Cells were 
resuspended in FACS buffer (PBS 1x, 2% FBS, 0,01% azide) and staining was performed in a 
final volume of 50 µL by incubating fluorochrome-conjugated antibodies with cells for 20 min 
at 4ºC in the dark. For primary human macrophages, CD14 was used as monocytic cell lineage 
marker while CD86 and CD206 were used as M1 and M2 specific markers, respectively. The 
following antibodies were used: anti-CD86-FITC (Immunotools, 2 µL/sample), anti-CD14-APC 
(Immunotools, 2µL/sample) and anti-CD206-PerCPCy5 (BD Biosciences Pharmingen, 5µL per 
sample). Unlabeled macrophages and labelling with isotype controls IgG1-FITC and IgG1-APC 
were used to define background staining. 
To evaluate levels of TLRs in THP-1 transfected macrophages the following antibodies 
were used: anti-CD11b-PE, anti-TLR4-Alexa Fluor 488 (both from eBioscience, 2µL of 
each/sample) and anti-TLR2-Alexa Fluor 647 (Biolegend, 2µL/sample).  Unlabeled THP-1 
macrophages and isotypes IgG1-PE, IgG2-FITC and IgG1-APC stainings were used as control.  
To perform HUASMC characterization by flow cytometry, adhered cells were detached 
using trypsin. Cells were resuspended in FACS buffer and stained as follows: single staining 
with anti-CD90-APC as positive marker (eBioscence, 5 µL/sample), CD10-APC and CD34-FITC 
as negative markers (Immunotools, 2 µL of each/sample); double staining with anti-CD90-APC 
and anti-CD34-FITC; unstained and IgGs (IgG1-APC and IgG1-FITC, Immunotools) as negative 
controls. 
Fluorescence was analyzed using FACS Canto II flow cytometer (BD Biosciences 
Pharmingen) with BD FACS Diva software, and 10 000 events were acquired per sample. 
Results were analyzed using FlowJo Software (http://www.flowjo.com/).  
2.4 Inverted fluorescence microscopy 
 
Presence of two important structural proteins, α-smooth muscle actin (α-SMA) and 
vimentin, in HUASMC was evaluated by fluorescence microscopy. 2.5x103 HUASMC were plated 
in top of 15 mm coverslips. Cells were then fixed with 4% paraformaldehyde (PFA) and 
permeabilized with 0.1% Triton X-100 for 5 min, washed with PBS and incubated with 1% BSA 
for 30 min. Staining was performed by incubating the cells for 1h with primary anti-α-SMA 
(Sigma) and anti-vimentin (Ab-2) (Thermo Scientific), diluted 1:400 and 1:100 in 1% BSA 
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respectively. Following washing, cells were incubated with 10 µg/mL of secondary anti-mouse 
Alexa 647 for 30 min. Finally, coverslips were placed on a microscope slide with the cells 
facing up. Fluoroshield with DAPI (4’,6-diamidino-2-phenylindole) mounting media (Sigma) 
was added to stain HUASMCs nuclei. Images were acquired using a 40x oil objective in an 
Axiovert 200M inverted fluorescent microscope (Zeiss). 
2.5 RNA extraction 
 
Total RNA was extracted from macrophages using TRIzol reagent (Invitrogen) according to 
the manufacturer’s instructions. Briefly, cell pellet was disrupted with 1ml TRIZOL and 
incubated for 5 min at room temperature. Next, 0,2 mL chloroform were added to the cells, 
inverted vigorously for 15 seconds and incubated for 5 min at RT. In order to obtain 3 phases, 
where the aqueous upper one contains RNA, a centrifugation 12000g for 15 min at 4ºC was 
performed. The upper phase was collected to a clean minicentrifuge tube. To precipitate 
RNA, sample was incubated for 5 min at RT with 0.5 mL of isopropanol. A second 
centrifugation was performed to obtain a RNA pellet which was washed with 1ml 75% ethanol. 
Sample was centrifuged 7500 g for 5 min at 4ºC and supernatant was discarded. Finally, RNA 
pellet was resuspended in 50 µL of DEPC-treated H20.  
RNA concentration was evaluated by measuring absorbance at 260 nm in NanoDrop 1000. 
Ratio of 260/280 nm and 260/230 nm range was between 1.8 and 2 suggesting no 
contamination by proteins or ethanol.  
2.6 Reverse transcription and real-time quantitative polymerase 
chain reaction  
 
miRNA expression was evaluated by Real-Time quantitative Polymerase Chain Reaction 
(RT-qPCR) using TaqMan miRNA assays. Firstly, cDNA was synthesized using 60 ng of RNA, 
TaqMan MicroRNA Reverse Transcription Kit (containing  buffer, dNTPs, RNAse inhibitor and 
reverse transcriptase) and gene specific stem-loop Reverse Transcription primers (miR-195 
and small nuclear RNA U6) (Applied Biosystems). The reaction was performed in a thermal 
cycler (MyCycler Thermal Cycler, Bio-Rad) using the following conditions: 16ºC – 30 min; 42ºC 
– 30 min; 85ºC - 5 min. cDNA samples were diluted in 50 µL nuclease-free water and qPCR 
reactions prepared in a 96-well PCR plate using cDNA, miR-195 or small nuclear RNA U6 
TaqMan probe and SsoAdvanced™ Universal Probes Supermix (Bio-Rad). RT-qPCR was carried 
out in iQ5 Real-Time PCR Detection System (Bio-Rad) for an initial 10 min at 95ºC followed by 
40 cycles of 15 seconds at 95ºC and 1 min at 60ºC. Experiments were performed in duplicate 
and small nuclear RNA U6 was used as reference gene. Relative expression levels were 
calculated using using the quantification cycle (Cq) method, according to MIQE guidelines.  
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2.7 Western blot 
 
2.7.1 Protein extraction and quantification 
 
Expression of proteins involved in TLR pathways was analyzed by western blot (WB). After 
transfections and/or stimulation with 100 ng/mL LPS + 20 ng/mL IFN-γ, THP-1 macrophages 
were harvested. Cells were lysed for 30 min on ice using lysis buffer (50 mM Tris-HCl - pH 7.4, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with protease inhibitors (200mM 
pMSF, 1mg/mL Leupeptin, 1mg/mL Aprotinin) and phosphatase inhibitors (50 mM NaVO3, 50 
mg/mL Na4O7P2, 10mM NaF 100x). Samples were centrifuged at 14000 rpm and supernatant 
containing protein was collected. Proteins were quantified by Lowry Method [204].  
 
2.7.2 Protein electrophoresis, blotting and detection 
 
After quantification, 20 ng of protein was added to buffer composed by 2-
mercaptoethanol (βME), (Sigma) and 4X Laemmli Buffer (BioRad) containing sodium dodecyl 
sulfate (SDS).  Samples were denatured at 94ºC for 5 min in a thermoblock and immediately 
placed on ice. 
Protein was run by SDS-Polyacrylamide Gel Electrophoresis (PAGE). The electrophoresis 
system was assembled, filling the inner space of the running module and the electrophoresis 
tank with running buffer 1x (prepared from 10x Tris/Glycine/SDS running buffer, Bio-Rad). 
Then, molecular weight standard and samples were loaded in the stacking gel wells. 
Electrophoresis was performed at 80V until the samples reach the resolving gel and at 100V 
until the end of the gel. Protein transfer (blotting) was performed at 100V for 1hour.  
Once blotting was completed, membrane was subject to immunodetection. Firstly, 
membrane was stained with Ponceau solution (0.2% w/v Ponceau, 5% acetic acid  in H2O) in 
order to evaluate the effectiveness of the transfer. Ponceau staining was completely removed 
by washing with TBS 1X-Tween 0.1% (Tris-base and NaCl in H2O and Tween 20) and the 
membrane was incubated in a blocking solution (Bovine Serum Albumin (BSA) 5% in TBS-Tween 
0.1%) at room temperature for 1 hour. Membranes were incubated overnight at 4ºC with anti-
p38 MAP Kinase, anti-phospho-p38 MAP Kinase (Thr180/Tyr182), anti-phospho-SAPK/JNK 
(Thr183/Tyr185), and anti-α-tubulin (all from Cell Signalling Technology), diluted at 1:1000 in 
2% milk TBS-Tween 0.1%. Next, membrane was washed in TBS-Tween 0.1% for 30 min and 
then incubated with secondary antibody Horseradish Peroxidase (HRP) labelled anti-rabbit 
(total p38, ph-p38, ph-SAPK/JNK and GAPDH) or anti-mouse (α-tubulin) both diluted 1:10000 
in 2% milk TBS-Tween 0.1%, for 1 hour at room temperature. The membrane was washed as 
previously indicated and detection performed using Amersham Enhanced Chemiluminescence 
(ECL) Western blotting detection reagents, from GE Healthcare (Figure 9). Membrane was 
transferred to an acetate sheet inside an X-ray film Hypercassette (GE Healthcare). In order 
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to obtain optimal detection, X-ray films were exposed for different time points in a dark 
room. Final developed films were analyzed using FIJI software (http://www.fiji.sc/). 
 
 
Figure 9 – Principle of ECL Western Blotting detection. Enhanced chemiluminescence is based on the 
emission of light during the horse radish peroxides (HRP) and hydrogen peroxide-catalyzed oxidation of 
luminol. The emitted light is captured on an X-ray film for qualitative or semi-quantitative analysis. 
 
 
2.8 Human umbilical artery smooth muscle cells recruitment: 
migration assay 
 
To evaluate miR-195 effect on recruitment of HUASMC by THP-1 macrophages, transwell 
migration assays were performed. Firstly, THP-1 cells were differentiated, transfected with 
miR-195 mimics or control and stimulated with 100 ng/mL LPS + 20 ng/mL IFN-γ in 500 µL of 
DMEM F12 without FBS for six hours (bottom compartment - BC). Then, 1x105 HUASMC in 500 
µL of DMEM F12 media without FBS were plated in Boyden chambers (inserts) with PET 
membranes of 8 µm pore size previously blocked with sterile 1% BSA (top compartment – TC) 
(Figure 10). To evaluate HUASMC recruitment, the following conditions were used: only 
stimulated THP-1 macrophages, THP-1 macrophages transfected with SCR and stimulated and 
THP-1 macrophages transfected with miR-195 and stimulated. Controls used were: only DMEM 
F12 with LPS+IFN-γ in the BC (without THP-1 macrophages) and only differentiated THP-1 
macrophages (non-transfected neither stimulated).  
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HUASMC were allowed to migrate through the membrane for 24h. Then, culture media 
was removed and membranes washed two times with PBS 1X. Cells were fixed with 4% PFA for 
15 min at RT. Insert membranes were washed again with PBS 1x and the inner side of the 
membrane was scrubbed with a cotton swab to remove non migrated cells. Membrane was 
removed and placed on a microscope slide, with the side containing migrated HUASMC facing 
up, and Fluoroshield with DAPI (Sigma) was used as mounting media.  Migrated HUASMC nuclei 
were counted in the inverted fluorescence microscope. Six random fields per membrane were 
selected and the results represent the sum of migrated cells in all the fields. 
 
 
 
 
 
Figure 10 – Schematic representation of migration assay. THP-1 macrophages in DMEM-F12 without 
FBS were plated in the wells of a 24 well plate (bottom compartment) and subjected to different 
stimuli. HUASMC were plated in inserts with PET membranes of 8 µm pore size (top compartment) and 
were allowed to migrate for 24 hours. 
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2.9 In silico target predictions 
 
In order to analyze potential targets of hsa-miR-195-5p, in silico predictions were 
performed by screening the following databases: 
miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/);  
miRanda (http://www.microrna.org/microrna/home.do); 
RNA22 (https://cm.jefferson.edu/rna22/Interactive/); 
TargetScan (http://www.targetscan.org/vert_71/).  
The search focused on genes involved in inflammatory pathways. miRNA FASTA format 
sequence annotations were obtained from the miRBase database (http://www.mirbase.org/). 
Target genes transcripts FASTA format sequence annotations were obtained from Ensemble 
(http://www.ensembl.org/). Only human protein coding transcript sequences were selected. 
The name of the target gene, the transcript ID and the interaction site were considered. 
2.10 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 6 (GaphPad Software, Inc.). 
D’Agostino-Pearson omnibus normality test was used to evaluate if the values follow a 
Gaussian distribution. In positive cases, paired t-test or one-way ANOVA were used to 
compare the samples. When data no pass the normality test, non-parametric test of Kruskal-
Wallis, followed by Dunns post-test comparing of user defined sets of data, were used to 
evaluate significant differences between the different samples. Statistical significance was 
considered when p<0.05 (* - p<0.05; ** - p<0.01). 
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Chapter 3 
Results 
3.1 miR-195 is involved in macrophage polarization 
 
At day 10 of in vitro culture, primary human monocytes are differentiated into 
macrophages. Cells were adherent to the plate with some cells showing a typical spindle-like 
morphology, while others exhibit a “fried egg” shape (Figure 11A). This was confirmed by 
flow cytometry, where more than 90% of the cells were positive for CD14, the 
monocyte/macrophage-lineage cell marker (Figure 11B), considering the IgG1 negative 
control. Therefore, monocytes were efficiently isolated from human buffy coats and 
successfully cultured in vitro for differentiation into macrophages. 
 
 
A                                                                    B 
 
Figure 11 – Human primary monocyte isolation and differentiation. A) Microscopy image of 
macrophages differentiated from monocytes at day 10 of culture (magnification of 200X). Scale bar 
50µm. B) Flow cytometry analysis of CD14 marker in macrophages. 
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Next, to induce macrophage polarization into pro-inflammatory M1 or anti-inflammatory 
M2c phenotypes, cells were treated with 10 ng/mL LPS or 10 ng/mL IL-10, respectively. 
Macrophage polarization was evaluated by flow cytometry using anti-CD86 and anti-CD206 
antibodies for M1 or M2c like macrophages. A representative profile is shown in Figure 12A. 
When the mean fluorescence intensity was quantified, results from 9 independent donors 
show significantly higher levels of cell surface marker CD86 in LPS-treated macrophages 
(mean fluorescence intensity = 856 ± 474) compared with IL-10-treated macrophages (mean 
fluorescence intensity = 334 ± 219) or with the non-treated macrophages (mean fluorescence 
intensity = 411 ± 240) (p<0.01) (Figure 12B). On the other hand, LPS-treated cells show 
significant lower levels of the mannose receptor CD206 (mean fluorescence intensity = 3332 ± 
1221) than IL10-treated cells (mean fluorescence intensity = 5099 ± 1824) (p<0.05). No 
significant differences were found between IL-10-treated macrophages and control group 
(mean fluorescence intensity = 5135 ± 2236) (Figure 12B). This may be partially explained if 
cells in the controls acquire a more M2-like phenotype.  
Globally, LPS-treated macrophages show higher CD86 and lower CD206 levels than IL-10-
treated macrophages, which allow to separate these cells into two subsets. 
After optimization of monocyte isolation, differentiation and macrophage polarization 
procedures, we search for miRNA with novel roles in macrophage polarization.  Total RNA 
from polarized macrophages from 9 different donors was isolated, but 2 donors were 
excluded from the analysis due to poor quality and low quantity.  Particularly, we evaluated 
the expression levels of miR-195 in polarized macrophages because  this miRNA plays a role in 
the cardiovascular system by inhibiting VSMC proliferation and migration [174], but its effect 
on inflammation modulation is unknown.  
Result show that miR-195 is significantly overexpressed in IL-10 treated macrophages 
compared with control (2.1 fold increase) or LPS treated (1.6 fold increase) groups (p<0.05) 
(Figure 12C).  Importantly, no significant differences in U6, which was used as a reference 
gene, were detected (Figure 12C). In conclusion, miR-195 is involved in M2 polarization 
following Il-10 stimulation. 
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Figure 12 – miR-195 expression levels in polarized macrophages. Macrophages were differentiated for 
10 days and polarized for further 3 days in presence of the indicated stimuli. A) Representative profile 
of macrophage polarization as analyzed by flow cytometry. B) Quantification of the mean fluorescence 
intensity of the M1 marker CD86 and the M2 marker CD206, across 9 different individuals, following LPS 
or IL-10 stimulation. Graphics represent mean fluorescence intensity values ± SD. C) Expression of miR-
195 by RT-qPCR in control, LPS and Il-10 treated macrophages, across 7 different donors. U6 was used as 
reference gene. Cq: quantification cycle. Statistical significance was considered when p<0.05 (* - 
p<0.05; ** - p<0.01; n.s. – non-significant). 
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3.2 Target predictions for miR-195 in TLR inflammatory 
pathway 
 
Following the previous results, we identified miR-195 as a potential anti-inflammatory 
mediator. Thus we determined if TLRs and other downstream proteins involved in the 
inflammatory pathway were predicted as a direct miR-195 target. 
Complementary base pair interactions between hsa-miR-195-5p sequence and transcript 
sequences of selected proteins were analyzed using four databases, which evaluate predicted 
interactions based on algorithms and validated miRNA-target interactions. miRWalk and 
RNA22 databases predict TLR2 as a target of miR-195 whereas ERK, JNK and p38 - all mitogen-
activated protein kinases during TLR signaling pathway - are also miR-195 target candidates 
by other algorithms/databases (Table 1). Moreover NFKB1 (p50) – a transcription factor 
downstream to the above mentioned kinases – is predicted by all the explored databases.  
Table 3 - Target predictions for hsa-miR-195-5p in different databases. 
Target 
Gene 
Transcript ID 
(Ensemble) 
Interaction site 
(by RNA22 and TargetScan) 
Databases 
m
iR
W
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m
iR
a
n
d
a
 
R
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A
2
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c
a
n
 
S
U
M
 
TLR2 ENST00000260010 
GCTG--TGCTCTGTTCCTGCTG 
||::     |||||  |||||: 
CGGTTATAAAGACA-CGACGAT 
1 0 1 0 2 
MAPK1 (ERK2) ENST00000215832 
GCAAGTCTTTTTAAATGCTGCTT 
|| |:| |||:|   |||||||  
CGGTTATAAAGA--CACGACGAT 
1 1 1 1 4 
MAPK3 (ERK1) ENST00000263025 
TTCAATCTCCCGCTGCTGCTGCTG 
 :||||      ||| |||||||: 
CGGTTA--TAAAGAC-ACGACGAT 
1 1 1 1 4 
MAPK8 (JNK1) ENST00000374189 
GTCATGCACCTTTG-GCTGCTA 
|:||      |:|| ||||||  
CGGT-TATAAAGACACGACGAT 
1 1 1 1 4 
MAPK9 (JNK2/SAPK) ENST00000452135 
ATCTTCCAGGTAGTGCTGCTT 
 :        :  |||||||  
CGGTTATAAAGACACGACGAT 
1 1 0 1 3 
MAPK11 (p38-β) ENST00000330651 
TCC-TGGTTTACCAGCTGCTG 
 ||   :|||    ||||||: 
CGGTTATAAAGACACGACGAT 
1 0 1 0 2 
MAPK12 (p38-γ) ENST00000622558 
GCCTTTCCAGTCCGAGCTGTTC 
|||       || | ||||:|  
CGG-TTATAAAGACACGACGAT 
1 1 1 1 4 
MAPK13 (p38-δ) ENST00000211287 
ACCGG--GAGCTGCTGCTGCTG 
 ||::     ||| |||||||: 
CGGTTATAAAGAC-ACGACGAT 
 
GGCAGTGATGCTGTGTTGGTT 
| ||:|:   |||||:|| |  
CGGTTATAAAGACACGACGAT 
1 1 1 1 4 
MAPK14 (p38-α) ENST00000229795 
ACC-TGGTTTCTGTTCTGTTG 
 ||   :||||||| |||:|: 
CGGTTATAAAGACACGACGAT 
1 0 1 1 3 
NFKB1 (p50) ENST00000226574 
GGCGGTG--GTAGTGGTGCTG 
| |::|:     ||| ||||: 
CGGTTATAAAGACACGACGAT 
1 1 1 1 4 
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3.3 miR-195 reduces TLR2 levels in THP-1 macrophages  
 
To address the biological effect of miR-195 in macrophage phenotype, gain-of-function 
studies were performed. In order to obtain high transfection efficiency, the monocytic THP-1 
cell line was used, instead of primary macrophages. THP-1 monocytes were plated with 100 
ng/mL of PMA and allowed to differentiate into macrophages for 48 hours. As shown in Figure 
13, differentiated cells acquire a macrophage-like morphology and become adherent to the 
plate.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 - THP-1 macrophages differentiation represented in two stages. (A) Cells immediately after 
100 ng/mL PMA addition (magnification of 200X). Scale bar 50 µm; and (B) fully differentiated THP-1 
macrophages after 48 hours of incubation with PMA (magnification of 200X). Scale bar 50 µm. 
 
 
Transfections of miR-195 mimics or a negative control (SCR) were tested using two 
different transfection reagents namely, Lipofectamine 2000 (Invitrogen) and HiPerFect 
(Qiagen). RT-qPCR results show that both reagents successfully transfected the cells. 
However, Lipofectamine 2000 was the most efficient, leading to higher miR-195 expression 
levels than HiPerFect reagent (Figure 14A). For this reason all the subsequent experiments 
were performed using this transfection reagent.   
Knowing that TLRs activation is implicated in atherogenesis, by starting signaling cascades 
that culminate in the production of pro-inflammatory cytokines, foam cell formation and 
activation of adaptive immunity, we next evaluated the expression of 2 TLRs. TLR2 that was 
predicted as a direct target of miR-195, and TLR4, the most studied TLR and a receptor for 
LPS stimulation. After transfection, THP-1 macrophages were stimulated with pro-
inflammatory stimuli and harvested after 36 hours. Results illustrated in Figure 14B (left) 
show that levels of TLR2 increase slightly upon stimulation for M1 phenotype. Importantly, 
when cells were transfected with miR-195 before M1 stimulation there was a significant 
decrease in TLR2 levels, compared with either M1 macrophages - 27% reduction - and M1 
macrophages transfected with SCR - 29% reduction (p<0.05). Levels of TLR4 were also 
evaluated. TLR4 decreased at the cell surface upon LPS (M1) stimulation, as expected due to 
(B) (A) 
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receptor internalization. However, despite it no longer decreasing in M1 miR195-
macrophages, this result was no different from that obtained with M1 SCR-transfected 
macrophages (Figure 14B, right).  
Taken together these results show that THP-1 are amenable to transfection, and miR-195 
reduces levels of TLR2 in pro-inflammatory conditions.  
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Figure 14 - miR-195 transfection and impact on TLR2 and TLR4 levels upon pro-inflammatory 
stimuli. A) Transfection efficiency for miR-195 mimics in THP-1 cells compared with scrambled control 
(SCR) was evaluated by RT-qPCR. Transfections were performed using Lipofectamine 2000 or HiPerFect 
Reagent. B) TLR2 (left) and TLR4 (right) levels on THP-1 were evaluated by flow cytometry after 
transfection with either miR-195 or SCR and after induction of M1-like macrophages with LPS and IFN-γ. 
Results from four independent experiments are shown (n=4). Statistical significance was considered 
when * - p<0.05. 
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3.4 miR-195 inhibits TLR2 signaling pathway 
 
To evaluate if TLR2 downstream proteins are regulated by miR-195, protein levels of p54 
(JNK1), p46 (SAPK/JNK2) and p38 were analyzed by Western Blot.  
Aiming to understand the maximum expression level, we first determined the levels of the 
phosphorylated forms of these proteins in different time points after M1 (LPS+IFN-γ) 
stimulation. Thus, differentiated THP-1 macrophages were induced by pro-inflammatory 
stimuli and cells were collected at different time points – 0, 5, 15, 30, 60 and 120 minutes.  
Results show that, under M1 stimuli, phospho p54 (JNK1), phospho p46 (SAPK/JNK2) and 
phospho p38 are generally expressed in the highest levels in time points 15 and 30 minutes 
(Figure 15A). These time points were selected for the subsequent experiments. 
We evaluated the levels of phosphorylated protein and total protein. Although differences 
in total p38 were not evident, phospho p54, phospho p46 and phospho p38 were all clearly 
downregulated by miR-195 in two independent experiments. As illustrated in Figure 15B, C, 
phospho p54 and phospho p46 are downregulated in macrophages transfected with miR-195 
compared to with the respective SCR controls after M1 stimulation for 15 and 30 minutes. 
After 15 minutes of M1 stimulation, macrophages overexpressing miR-195 exhibit a small 
reduction of 17% in phospho p54 (Fold change to SCR (Fc) = 0.8347 ± 0.1274) and 41% in 
phospho p46 levels (Fc = 0.5776 ± 0.0057) compared with M1 macrophages transfected with 
SCR. After 30 min of M1 stimulation, phospho p54 levels (Fc = 0.7512 ± 0.0189) show a 25% 
reduction while phospho p46 (Fc = 0.5776 ± 0.0261) maintains the reduced levels in miR-195-
macrophages compared with SCR control.  Regarding p38, both total and phosphorilated 
forms of the protein were tested. No differences were detected in total p38 protein levels 
(Fig. 5B, Annex 1 - Figure 21), which suggests p38 is not a direct target of miR-195. Regarding 
phospho p38 levels, after 15 minutes of M1 stimulation no differences are detected (Fc = 
0.9517 ± 0.1409); however, 30 minutes after M1 stimulation, phosphorylated levels of this 
protein (Fc = 0.5905 ± 0.0216) are diminished by 41% in miR-195 transfected THP-1 
macrophages (Figure 15B,C).  
In conclusion, miR-195 impacts an inflammatory pathway through downregulation of 
phosphorylated forms of intracellular proteins downstream of TLR2.  
40 
 
 
A 
 
 
 
B 
 
 
 
C 
 
 
 
 
Figure 15 – miR-195 downregulates phospho p54, phospho p46 and phospho p38. A) Western blot for 
ph-p54, ph-46, ph-p38 after LPS+IFN-γ stimulation in different timepoints.  B) Western blot for ph-p54, 
ph-46, total p38 and ph-p38 in 9 different experimental conditions. C) Quantification of ph-p54, ph-46, 
ph-p38 levels in two independent experiments. α-Tubulin was used as normalizer. 
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3.5 Expression of miR-195 in macrophages inhibits smooth 
muscle cells recruitment  
 
The impact of miR-195 expression in macrophages was also evaluated at a functional 
level. 
In advanced stages of atherosclerosis pro-inflammatory macrophages promote the 
recruitment of smooth muscle cells to the lesioned area which also become lipid loaded foam 
cells producing pro-inflammatory cytokines. Thus, we performed migration assays using 
human umbilical artery smooth muscle cells (HUASMC) to evaluate if miR-195-THP-1 
macrophages under pro-inflammatory stimuli impact the capability to recruit these cells.  
Firstly, culture conditions for HUASMC were optimized. Cells were cultured in T75 flasks 
previously coated with collagen until confluent. As shown in Figure 16, HUASMC grown in a 
collagen coated surface have increased proliferation and reach the confluence more easily 
than cells grown in non-coated surface. This was expected as it better mimics the in vivo 
growth environment of these cells.  
 
 
Figure 16 – Human umbilical artery smooth muscle cells culture.  Left image shows HUASMC after 5 
day culture in a pre-coated flask and right image represents the same cells in the same culture 
conditions in a non-coated flask (magnifications of 100X). Scale bar 100 µm. 
 
We further characterized HUASMC cells evaluating by flow cytometry the levels of surface 
markers previously described to be part of the marker profile for the evaluation of HUASMCs 
[205]. Thus, CD90 was used as positive marker, CD10 and CD34 (endothelial marker) were 
used as negative markers. Results clearly show high levels of CD90 (99,9% CD90+) in HUASMCs 
that, in turn, do not express CD10 nor CD34 (Figure 17). Furthermore, we evaluated, by 
inverted fluorescence microscopy, the expression of two important SMC structural proteins, 
α-SMA and vimentin. HUASMC positively express both markers, as shown in Figure 18A,B. 
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Figure 17 – Characterization of human umbilical artery smooth muscle cells by flow cytometry. 
Histograms represent flow cytometry results for CD10, CD34 and CD90. Dot plot graphic show double 
staining with CD90 and CD34. 
 
 
 
  
 
Figure 18 – Evaluation of human umbilical artery smooth muscle cells markers by inverted 
fluorescence microscopy. (A) Cells show positive staining for α-SMA marker. (B) Cells show positive 
staining for vimentin marker. Microscope images obtained using a 40x oil objective. Scale bar 20 m. 
 
(A) (B) 
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Knowing that the HUASMC cells were expressing the correct markers we proceeded to 
evaluate their ability to migrate in response to macrophages transfected with miR-195.  
First we evaluated the capacity of HUASMC to migrate in response to FBS, a non-specific 
stimulus, to optimize migration experiments. Two densities of cells (5 x 104 and 1 x 105 cells) 
were plated in serum-free medium in the top compartment of a transwell and were allowed 
to migrate for 6 or 24 hours, using FBS as a chemoattractant. Figure 19A illustrates the nuclei 
of the cells that crossed the membrane pores and are found on the bottom side of the 
transwell membrane. As expected, results show higher number of migrated HUASMC (7-fold 
difference) after 24 hours compared with 6 hours (Figure 19B). Furthermore, the initial 
number of HUASMC placed on the top compartment influenced the final number of migrated 
cells (Figure 19B). Thus, 1 x 105 HUASMC plated on top and time point of 24h performed the 
best and were the selected conditions for the following experiments. 
 
A                                                                                                         
 
space  
 
B 
 
 
 
Figure 19 – Evaluation of human umbilical artery smooth muscle cells migration ability. A) Inverted 
fluorescence microscope images representing migrated cells stained with DAPI from an initial number of 
1 x 105 HUASMC and allowed to migrate for 6 (left) or 24 hours (right). Scale bar 100 µm. B) Migratory 
profile of HUASMC in transwells following a nutrient gradient. FSB was used as a chemoattractant. 
(a) 
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Finally, the effect of miR-195-THP1-macrophages on HUASMC migration was determined.  
Results show that THP-1 macrophages transfected with miR-195 in pro-inflammatory 
conditions have less capability to recruit HUASMC compared with non-transfected and SCR-
transfected pro-inflammatory THP-1 macrophages (p<0.05). In fact, transfection of M1 
macrophages with miR-195 reduced their capability to recruit HUASMC in almost 40% 
compared with non-transfected M1 macrophages and in 50% compared with M1 macrophages 
transfected with SCR (Figure 20). 
 
 
 
Figure 20 - miR-195 reduces the capability of THP-1 macrophages to recruit human umbilical artery 
smooth muscle cells. HUASMC migration in different conditions. Experiments were performed in 
triplicates. Statistical significance was considered when * - p<0.05. 
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Chapter 4 
Discussion  
4.1 Primary cells versus cell lines in vitro cultures for the study 
of macrophage polarization 
 
In the current work primary human monocyte-derived macrophages and macrophages 
differentiated from a human monocytic cell line were used. The efficiency of monocyte 
isolation from human buffy coats and the subsequent differentiation into macrophages can be 
affected by methodological procedures, but also by the biological variability associated with 
different individuals. In fact, this variability explains the need to test several different donors 
in order to establish a trend in the normal population. Primary monocytes/macrophages 
should provide experimental results most similar to natural biological mechanism than the use 
of cell lines [206]. Generally, primary cells retain normal morphology, cellular function, 
growth characteristics, cellular markers, signaling and genetic integrity when cultured for 
short periods of time, better replicating what happens in vivo [162, 207]. However, the short 
life time of these cells in culture, and their low tolerance levels to exogenous or 
environmental factors, such as transfections, make them difficult to manipulate.  For that 
reason, in this study a monocytic cell line (THP-1 cell line) was used to perform transfection 
assays [171, 208, 209]. Cell lines by definition have been altered or “transformed” in some 
manner, either naturally or by manipulation in the laboratory, departing from the native 
cellular functions and growth characteristics found in normal primary cells [210]. However, 
although cell lines typically exhibit abnormal or uncontrolled metabolic function and 
proliferative capacities in culture as a result of intracellular changes, they were generated to 
answer particular research questions and have the benefits of lower cost, longer time in 
culture and elevated output signals for assay development [211]. In this work, we used THP-1 
cell line which is a human monocytic cell line derived from acute monocytic leukemia 
patients. This cell line is a commonly used model in macrophages studies as these cells 
feature and share many monocyte/macrophages- like characteristics. When adhered and 
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differentiated into macrophages, these cells exhibit the heterogeneity characteristic of 
primary macrophages, with some cells presenting rounded shape and others presenting 
stretched forms [212]. Differentiated THP-1 macrophages also express surface receptors 
similar to primary macrophages such as CD11b, CD14, TLR2 and TLR4 [212]. The cytokine 
production profile of THP-1 cells and primary PBMCs can also be compared, as they produce 
similar levels of IL-1β and TNF-α after stimulation with LPS [213]. Moreover, they have been 
extensively used as model for transfections of macrophage like cells, exhibiting low cell death 
and high transfection efficiency [167, 177]. These similar characteristics make these cells the 
most attractive to substitute and overcome the practical issues associated to the primary 
macrophages cultures.  
4.2 miR-195 as a modulator of inflammation 
 
miRNAs play crucial roles in the development of cells of the immune system [214]. As 
discussed before, macrophages can present different phenotypes, depending on the cytokine 
environment they encounter. The gene expression profile of each macrophage subset has 
been lately studied in order to understand in which manner these differently expressed 
miRNAs influence the immune functions of polarized macrophages [215].  
Previously, miR-195 was showed to play a role in cancer, by inhibiting cell cycle 
progression and proliferation of different cancer cell types [216–218], and in the 
cardiovascular system by regulating VSMC phenotype, migration and preventing neointimal 
formation [174]. Macrophages and SMCs represent major players in the pathogenesis of 
atherosclerotic vascular diseases. Activated pro-inflammatory macrophages promote pro-
atherogenic functions of SMCs [219]. For this reason we evaluated if these anti-atherogenic 
miR-195 could act through macrophages, inhibiting their pro-inflammatory action, and 
conditioning their relation with SMCs.   
Herein, we describe for the first time that miR-195 is overexpressed in IL-10-treated 
macrophages. This novel finding lead us to further explore its biological function and 
investigate if increased expression of miR-195 could inhibit the mechanisms involved in the 
M1 macrophage polarization, following other described miRNAs such as miR-125a, which is 
known to inhibit the classical macrophage activation and to decrease secretion of some 
inflammatory cytokines (IL-6 and TNF-α) [135, 169], and miR-146a known to target TLR4 and 
thereby inhibiting the activation of TLR4-dependent signaling pathways  [135].  
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4.3. miR-195 in TLR signaling pathway 
 
TLRs recognize distinct pathogen-associated molecular patterns and play a critical role in 
innate immune responses [40]. These surface receptors participate in the first line of defense 
against invading pathogens and play a significant role in inflammation, immune cell 
regulation, survival, and proliferation [220].  The activation of TLR-dependent signaling 
pathways promotes the consecutive phosphorylation of several molecules leading to 
activation of MAP kinases (JNK, p38 MAPK) and NF-κB. At the end of the TLR signaling 
cascade, in the nucleus, transcription factors are activated inducing the production of pro-
inflammatory cytokines, such as IL-1β, IL-6, IL-8 and TNF-α [40, 221].  
We investigated if the miR-195 could affect these pathways, starting from the receptor 
and progressing to the intermediate molecules involved. The results from computational 
miRNA target prediction algorithms included many potential targets, but TLR2, MAP kinases, 
JNK/SAPK and p38 genes were selected as they yielded particularly high scores. Thus, we 
analyzed the expression of TLR2 and the results showed a significant reduction of this 
receptor in THP-1 macrophages transfected with miR-195, suggesting that the expression of 
this surface receptor can be regulated by miR-195. TLR2 expression regulation through 
miRNAs has been described by other authors. Philippe et al. proved by luciferase assays that 
Tlr2 mRNA is a direct target of miR-19 in rheumatoid fibroblast-like synoviocytes, and 
Benakanakere et al. showed modulation of TLR2 expression in human gingival epithelial cells 
by miR-105 [222, 223]. However, to the best of our knowledge, miRNAs targeting TLR2 in 
human macrophages were so far unknown. 
Following in the same line, the levels of p54 (JNK1), p46 (JNK2/SAPK) and p38 MAPK 
proteins were investigated by western blot. Algorithms can predict hundreds of transcripts as 
potential miRNA targets in silico [224]. However, generally only a small portion is 
experimentally validated [225–227]. Although p38 total protein levels were not altered, the 
activated/phosphorylated form was visible downregulated by miR-195 as well for p54 (JNK1) 
and p46 (JNK2/SAPK) activated/phosphorylated forms. JNK isoforms and p38 MAPKs have 
similar mechanisms of activation [228, 229]. Specifically, both are activated by small GTPases 
of the Rho family, such as CDC42 [230]. This transcript has already been reported to be a 
target of miR-195 [174], which could partially explain the inhibition of ph-p38, ph-p46 and 
ph-p54, that we detected by western blot.  
Together these results indicate that miR-195 efficiently inhibits the pro-inflammatory TRL 
signalling pathway, specifically p38 and JNK pathways, reinforcing the idea that this specific 
miRNA acts as an anti-inflammatory agent in macrophages.  
48 
 
 
4.4 miR-195 in smooth muscle cells recruitment by 
macrophages 
 
In advanced states of atherosclerotic lesions, macrophages secret high levels of pro-
inflammatory cytokines and chemokines which perpetuate the inflammatory process and 
promote migration of VSMC into the intima [91]. There, SMC proliferate and secrete pro-
fibrotic mediators, resulting in the fibrous cap formation. At some stages this 
fibroproliferative response is believed to be a defensive, protective, physiologic response to 
injury, designed to wall off, contain, enclose, or sequester the injurious agent, and then to 
assist in resolution of the injury [231]. However, atherosclerotic SMC are described to switch 
to a macrophage-like phenotype also by uptake lipids [232]. As result of lipid over-ingestion, 
resident and recruited SMC die because of toxic chemical agents, such as oxidized LDL. The 
death of the SMC leads to discharge of the ingested lipids and other cellular elements into the 
extracellular space, and to the degeneration of non-viable fibrous tissue [16]. At this point 
the fibrous cap covers a mixture of apoptotic leukocytes, lipid, and debris which may form a 
necrotic core that thins the fibrous cap, already diseased and weakened by dysfunctional 
SMC, leading to plaque rupture [231]. Thus, the fibrous cap has become a pathologic 
component of the disease process, and not a protective structure designed to enclose the 
necrotic core. 
Previous work had shown that miR-195 can directly inhibit SMC proliferation and migration 
[174]. Moreover, our migration assay results show that also macrophages overexpressing miR-
195 lose their ability to promote SMC recruitment. We concluded that miR-195-overexpressing 
macrophages stimulated with a pro-inflammatory stimulus recruited significantly less SMC 
than M1 macrophages transfected with SCR or the non-transfected M1 macrophages. This is 
the first evidence showing that modulation of macrophage polarization thought miR-195 has a 
paracrine effect on SMC. 
Although chemokines and cytokines secreted by miR-195-macrophages were not 
determined so far, it is likely that pro-inflammatory cytokines such as MCP-1, IL-1β, IL-8 
and/or TNF-α, known to promote the recruitment and proliferation of SMC, are decreased 
[233, 234].  
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Chapter 5 
Conclusions and future perspectives 
The results discussed above indicate that miR-195 may have a dual role in atherosclerosis 
and other cardiovascular diseases. On one hand, it modulates inflammation by decreasing 
TLR2 pro-inflammatory pathway in macrophages. On the other hand, miR-195 reduces 
macrophage capacity to recruit SMC. Therefore, we identified miR-195 as a new potential 
agent for future anti-inflammatory and anti-atherogenic therapies in the context of 
cardiovascular research. Since macrophages action is present in several key processes of 
plaque development, regulation of miR-195 expression could have beneficial outcomes in the 
treatment of atherosclerosis. A manuscript describing and discussing these results is being 
prepared to be submitted for publication.  
Specific modulation of miRNAs by pharmacological compounds is an attractive therapeutic 
approach that has been increasingly studied. Antisense oligonucleotides (ASOs) have been 
used to specifically target and inhibit miRNAs overexpressed in atherosclerosis [235, 236]. 
However, several issues related to risks of unintended targeting on other RNA molecules and 
to the lack of accuracy methods to test ASOs efficacy need to be overcome [237].  
In order to upregulate specific miRNAs described as anti-atherogenic, an emerging 
therapeutic approach is the delivery of miRNAs. In particular, Lovren et al. described a 
lentiviral delivery of miR-145 which is highly expressed in human aortic SMC and regulates 
their fate and plasticity [238]. The SMC-targeted miR-145 treatment in apolipoprotein E 
knockout mice markedly reduced plaque size in aortic sinuses, ascending aortas, and 
brachiocephalic arteries and also promoted plaque stability by reducing the necrotic core 
area and increasing plaque collagen content [238].  
Thus, in the future it would be interesting to optimize delivery systems for miR-195. Our 
collaborators from Laboratory of Macromolecular Synthesis and Functionalization (Zhejiang 
University – Hangzhou, China) developed a new type of non-viral PEG-detachable gene vector 
for redox-responsive gene delivery [239]. The mPEG–SeSe–PEI polymer efficiently condensed 
DNA into tightly packed spherical nanoparticles about 80 nm in size, which showed excellent
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 extracellular stability under physiological conditions and exhibited easily intracellular 
cleavage resulting in facilitated dePEGylation and DNA release [239]. We tested the ability of 
this polymer to condensate the negative control (SCR) used in the previous experiments, and 
the results were promising. DLS analysis with a Zetasizer Nano ZS (Malvern) nanoparticle 
analyzer revealed nanoparticles with 233.9 ± 36.9 nm diameter (Annex 2 - Figure 22), which 
might be suitable for in vitro experiments. Optimization of the procedures is still ongoing and 
transfection efficiency will be tested in a near future. Additionally, the impact of miR-195 in 
other cell types, including in endothelial cells, will be addressed in the next future. This is of 
crucial importance as we intend to test these nanoparticles not only in vitro but also in 
animal models. Improvement of miRNA delivery systems to impair atherogenesis, through 
modulation of inflammation or reduction of SMC recruitment, may unravel new future 
treatments for arthrosclerosis.  
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Annexes  
 
Annex 1 – Quantification of total p38 protein by Western Blot 
 
 
A 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 – Quantification of total p38 and phospho p38 levels normalized with total p38. A) Total 
p38 was evaluated in one experiment and their levels were normalized with α-tubulin. B) Phospho p38 
levels were also quantified after normalization with total p38 levels of the same experiment.  
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Annex 2 – mPEG-SeSe-PEI / SCR polyplexes size evaluation by DLS 
 
 
 
Figure 22 – mPEG-SeSe-PEI/SCR polyplexes size evaluation by Dynamic Light Scattering. mPEG-SeSe-
PEI/SCR polyplexes formation were performed in Hepes buffer (pH 7.4). Particle size was determined by 
Dynamic Light Scattering using a Zetasizer Nano ZS. Six independent measures were performed (mean ± 
SD). 
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